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GENERAL INTRODUCTION 
Since the origin of life, man has been interested in food for 
survival, enjoyment and economic benefit. This interest has cultivated 
curiosity in not only the variety of foodstuffs and their composition, 
but also in the processes involved in the taking in and utilization of 
food substances by which growth, repair and maintenance of activities 
in the body are accomplished. These processes of ingestion, absorbtion 
and metabolism together are referred to as nutrition. Nutrition has 
developed as a unique area of science, as daily each person is 
interested in nutrition for their personal well-being. 
Man's curiosity inspired scrutiny into which foodstuff components 
resulted in improved health, enjoyment and longevity. The "father of 
medicine," Hippocrates (460-377 B.C.), reflected some of the earliest 
beliefs on this subject when he stated to the ancient Greeks, "There is 
but one food, but there exist several forms of food" (Mendel, 1923). 
Later, the Roman physician Galen (130-200 A.D.) theorized that during 
digestion all food was changed into a single substance that maintained 
life. However, with time man dissected foodstuff components into fats, 
carbohydrates, proteins, vitamins, minerals and water, and it was 
realized that all nutrients combined in a balanced arrangement were 
necessary for healthful sustenance. 
The French physiologist, Fancois Magendie, was the first to note 
the need for protein in the diet. In a memoir written in 1816, "Food 
Substances without Nitrogen," he reported a trial in which dogs fed 
diets consisting only of sugar, fat and distilled water became emaciated 
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and died. Magendie concluded that animals cannot live without 
nitrogenous food (Olmsted, 1944). In 1839, the Dutch chemist Mulder was 
the first to suggest the term "protein" for the compound that 
"unquestionably is the most important of all known substances in the 
organic kingdom. Without it, no life appears possible on our planet" 
(Mendel, 1923). 
Approximately 150 years have passed since these initial 
observations. During this period, protein and its relationship to 
bodily functions have been critically researched. Interestingly, with 
all of the research in this area, the initial premise still withstands: 
protein is essential for life. Protein and its constituent amino acids 
are known to be required for many important physiological processes 
(e.g., hormones and enzymes for control of metabolism, plasma proteins 
for metabolite transport) and anatomical structures (e.g., muscle 
tissue, connective tissue, nucleoprotein). 
Malnutrition is one of the major problems facing the world today, 
as it has been estimated that 40% of the world's population is 
malnourished. Additionally, protein deficiency is considered to be the 
major contributor to this malnutrition. Kwashiorkor, a disease in which 
energy is adequate but protein is severely limiting, is widespread 
throughout the world, particularly where grain is the major dietary 
foodstuff and protein source. Kwashiorkor and other severe forms of 
protein malnutrition severely diminish the quality of life, resulting 
in reduced growth and maturation, in decreased resistance to infective 
agents and in diminished intellectual and learning capabilities. 
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With the already existing shortage of quality protein and the 
foreseen increase in world-wide population, the world-wide supply of 
protein must be increased. Animal protein production needs to be an 
important part of this increase. Animal production provides greater 
than half of the world's protein (CAST, 1975). In addition to quality 
protein, animal products provide one-fourth of the energy consumed, 
four-fifths of the calcium consumed, two-thirds of the phosphorus 
consumed, significant amounts of other minerals and vitamins (especially 
vitamin and a variety of important byproducts. 
Ruminants are particularly unique in that they can convert non­
protein nitrogen and low-quality protein to a high-quality foodstuff for 
human consumption. Forages, which are poorly digested by humans, 
contribute 70% of the protein consumed by dairy cattle, 60% of the 
protein consumed by growing beef cattle and 85% of the protein consumed 
by growing lambs (Moore et al., 1967). The beef industry has been 
estimated to provide Americans with 12% of their total food-energy 
intake and 23% of their total protein intake, the highest of any 
agricultural commodity (CAST, 1979). 
Not only will the world need to increase the production of protein, 
but an increase in the efficiency of this production is also necessary. 
An improvement in efficiency, with an equal number of inputs, would 
naturally increase the amount of protein produced. However, an 
improvement in efficiency may also be a mechanism to allow the 
agricultural community to maintain or increase a margin of profit by 
requiring fewer inputs. Finally, if society and policy-makers decide 
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that more grain needs to be directed to human consumption, there would 
be less available for livestock and livestock would be required to be 
more efficient to compete. 
The efficiencies at which animals produce food protein are included 
in Table 1. Although it should be remembered while interpreting these 
data that much of the ruminant feed comes from sources poorly utilized 
by humans, it is clear that there is considerable margin and need for 
improvement in efficiency. 
Table 1. Efficiency of various livestock in converting feedstuffs to 
edible nutrients^  
-Efficiency of nutrient conversion, %-^  
Livestock Crude protein Energy 
Nonruminants: 
Broiler 23 11 
Turkeys 22 9 
Hens (eggs) 26 18 
Swine 14 14 
Ruminants : 
Dairy cattle 25 17 
Beef cattle 4 3 
Lambs 4 3 
S^ummarized from Wedin et al. (1975). 
E^fficiency of nutrient conversion is equal to the amount of 
nutrient consumed divided by the amount of nutrient produced multiplied 
by 100%. 
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In animals used for production of protein, energy is expended for 
various biological functions. While a certain amount of protein 
degradation is necessary for normal biological function, unnecessary 
protein turnover would result in nutrient waste. Therefore, decreasing 
protein turnover is a possible method to improve animal protein 
production. Decreased protein turnover would result in less energy 
being required to produce a kg of meat, milk or egg protein. The object 
of the following research is to examine the effect of O^ ketoisocaproate, 
which has been proposed to reduce protein turnover, on growth, 
efficiency of feed conversion, muscle and fat deposition and protein 
metabolism in growing cattle and lambs. 
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REVIEW OF THE LITERATURE 
General Leucine and KIC Metabolism 
Biochemical pathways and enzvmes Leucine is a 6-carbon amino 
acid ((CHg)2CHCH2CH(NH2)C00H) that is essential to mammalian tissues as 
it cannot be synthesized de novo within the body. It belongs to the 
class of amino acids called branched-chain amino acids (BCAA) of which 
isoleucine, valine and leucine are the only members. The major 
difference between the metabolism of the three amino acids is the 
products produced. Whereas leucine is ketogenic, valine is glucogenic 
and isoleucine is both ketogenic and glucogenic. 
Leucine in the body is derived from three sources; protein 
breakdown, dietary leucine and transamination from the o^ ketoacid, 
D(-ketoisocaproate (KIC). Leucine either can be incorporated into 
protein or transaminated to KIC. Leucine is converted to KIC via the 
enzyme BCAA transaminase, which is specific for all BCAAs, and leucine 
transaminase, which is specific for leucine only. This transamination 
is reversible, and KIC can be converted back to leucine. 
KIC is irreversibly oxidized to isovaleryl CoA via the 
mitochondrial enzyme branched-chain keto acid (BCKA) dehydrogenase. The 
activity of this enzyme is stimulated by increased dietary protein, 
increased dietary leucine or KIC and diabetes. Phosphorylation 
inactivates the enzyme. In addition to the conversion of KIC to 
isovaleryl CoA, KIC can be decarboxylated to hydroxy -^  -me thyIbutyrate 
(HMB) in the cytosol by KIC oxygenase. It is thought that HMB is 
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excreted in the urine. 
Isovaleryl CoA is sequentially converted to y^ -methylcrotonyl CoA, 
-^methylglutaconyl CoA and finally ^ -hydroxy-^ -methylglutaryl CoA (HMG 
CoA) within the mitochodria. HMG cleavage enzyme metabolizes HMG CoA to 
acetoacetate plus acetyl CoA. Acetoacetate can cross the mitochondrial 
membrane and be converted to ketone bodies (acetone and 
-^hydroxybutyrate) or be sequentially converted to acetoacetyl CoA and 
HMG CoA. In the cytosol, HMG CoA can be metabolized to mevalonic acid 
via HMG CoA reductase. Mevalonic acid continues on to cholesterol and 
other steroid synthesis. Therefore, the end products of leucine and KIC 
metabolism include carbon dioxide, ketone bodies, HMB and cholesterol. 
Physiology of BCAA and BCKA metabolism The distribution of the 
enzymes involved in BCAA metabolism varies with different body tissues. 
BCAA transaminase was not detected in rat liver but was detected in the 
brain, muscle and kidney (Khatra et al., 1977). Mimura et al. (1968) 
noted BCAA transaminase activity in rat small intestine. When KIC was 
added to kidney perfusate, leucine was released at a rate amounting to 
15 to 25% of the total KIC disappearance (Mitch and Chan, 1978). 
Interestingly, KIC, but not leucine and isovaleryl Co A, addition 
increased the rate of transamination. It was suggested that KIC may 
control transamination activity, therefore regulating the metabolism of 
BCAA (Mitch and Chan, 1979). 
In the rat, 70% of the total BCKA dehydrogenase activity is found 
in the liver and 10% in the muscle (Bassler and Fietrek, 1983). In man, 
the liver accounts for 30% of the total BCKA dehydrogenase activity 
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whereas muscle tissue accounts for 60% of the activity (Khatra et al., 
1977). Therefore, the conditions for an oral dose of KIC passing 
through the liver is more favorable in man than in the rat. 
These differences in where the enzymes are found result in 
important differences in the site of metabolism between BCAA versus 
BCKA. It is thought that BCAA undergo very little metabolism in the 
liver and gut tissues, but rather are metabolized mainly by muscle and 
somewhat by adipose tissues. Miller (1961) first proposed that a 
significant amount of BCAA was metabolized by extrasplanchnic tissues. 
Early canine liver perfusion studies indicated that only 15% of a BCAA 
load was taken up by the liver (McMenamy et al., 1962). In vivo studies 
in unanesthetized dogs confirmed that most BCAA (-70%) escape the liver 
and are taken up by extrasplanchnic tissues after the ingestion of a 
protein meal (Elwyn et al., 1968). In another study with dogs, 
Bloomgarden et al. (1981) found that 95% of the BCAA escaped the liver 
and were taken up by the extrasplanchnic tissues (Bloomgarden et al., 
1981). It was noted in humans that most of the BCAA were taken up by 
extrasplanchic tissues after the ingestion of a protein meal (Aoki et 
al., 1976; Wahren et al., 1976). In a study with lambs, dietary leucine 
was absorbed at the rate of 1.1 mmol/hr and the liver removed .4 mmol/hr 
(33% removed; Wolff et al., 1973). 
In studies with isolated rat muscle (Chang and Goldberg, 1978b) and 
perfused rat muscle (Hutson et al., 1979), it was concluded that 
skeletal and heart muscle were the major if not the only site for 
metabolism of BCAA. Abumrad et al. (1982a) intravenously infused amino 
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acids Into the human forearm and measured the balance of amino acids 
across this site. Although 35% of the amino acid solution Infused was 
BCAA, BCAA accounted for 49% of the total amino acid uptake of the 
forearm. They concluded that, while skeletal muscle is an Important site 
for the uptake of BCAA, it cannot account for more than 65% of the load 
administered. These data, across a variety of species, similarly 
emphasize the minimal role of the liver and the major role of the muscle 
to metabolize BCAA. 
Although muscle tissue is thought to be the primary contributor to 
leucine metabolism, adipose tissue also has the ability to be very 
active In the metabolism of leucine (Rosenthal et al., 1974; 
Wijayasinghe et al., 1983). 
In direct contrast to leucine and BCAA, KIC and BCKA have been 
implicated to undergo extensive catabolism in splanchnic tissues. As 
noted earlier, there is considerable BCAA transaminase activity in 
intestinal and hepatic tissues (Bassler and Pietrek, 1983). Weber et 
al. (1977) infused ketoaclds into the jejunum of fasting dogs to measure 
transport across the gut and found 20 umol KIC/(cm*hr) disappeared from 
the lumen of the jejunum. Of the total KIC absorbed, 8% appeared in 
mesenteric blood as leucine and 34% of the absorbed KIC was degraded by 
the gut wall. Similar studies utilizing rat Jejunum and iliac segments 
of intestine also reported significant release of infused KIC as 
leucine, indicating partial transamination of KIC in the gut wall (Weber 
et al., 1979). 
Abumrad et al. (1982b) extensively examined the site of KIC 
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metabolism after administering an oral load of KIC to dogs. They found 
that after about one hour approximately 63% of the KIC load was absorbed 
as KIC, while 23% was transaminated across the gut and released as 
leucine. The liver removed 35% of the administered load, of which 33% 
was transaminated to leucine and 66% was converted to ketone bodies. 
Therefore, 27% of the administered load passed through the gut and liver 
tissues as unmetabolized KIC. Of this, approximately 12% was 
transaminated across the kidneys to leucine, leaving only 15% of the 
original dose for use by peripheral tissues. No mention was made as to 
uptake via muscle versus other peripheral tissues such as adipose or 
brain. 
Similar results were obtained with the rat, where only 12% of an 
oral load of KIC passed through the gut and liver unchanged (Bassler and 
Pietrek, 1983). KIC was not detected in feces from these animals. 
KIC has been shown to be rapidly catabolized by muscle. In early 
studies in liverless dogs where 1 g of KIC was infused intravenously, 
there was no increase in the arterial plasma, suggesting a very rapid 
uptake (McMenamy et al., 1965). The half-life of an intravenous dose 
(1 mmol) of KIC was found to be 10.5 min (Bassler and Pietrek, 1983). 
Intra-arterial infusion of KIC (34.3 umol/min) into the human forearm 
resulted in 52% of KIC extracted in a single passage of KIC (Pozefsky 
and Walser, 1977). Leucine was the only amino acid released in 
increased amounts and accounted for 31% of the KIC extracted. Alanine, 
histidine and glycine release were significantly lowered, indicating that 
these amino acids may be the nitrogen donors for the conversion of KIC 
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to leucine. 
In humans and rats, starvation Increases plasma BCAA 
concentrations, whereas protein deprivation decreases plasma BCAA 
concentrations within one day. Changes in the plasma concentrations 
reflect changes predominantly in muscle and secondly in the liver. The 
increased muscle protein breakdown during starvation, which supplies 
substrates for enhanced gluconeogenesis in the liver and enhanced BCAA 
oxidation in the muscle, is the major mechanism of hyperbranched-chain 
aminoacidemia during starvation. The main factors in the development of 
hypobranched-chain aminoacidemia during protein deprivation are absence 
of exogenous amino acids as well as curtailed protein breakdown (Adibi, 
1976). 
Leucine and KIC metabolism were measured in lambs fed either high-
energy or low-energy diets (Nissen and Ostaszewski, 1985). Less than 
20% of the total leucine was transaminated to KIC and 42% of the KIC was 
converted to leucine, indicating that transamination is low in 
ruminants. Increased dietary energy decreased leucine incorporated into 
protein, leucine oxidation and interconversion of KIC and leucine. 
Starvation in lambs produced a decrease in plasma BCAA and BCKA 
(Bergman and Heitman, 1978; Pell et al., 1986). Unlike humans and rats 
where BCAA from proteolysis during starvation are catabolized locally, 
lambs fasted 3 to 6 days released considerable BCAA from the hind 
quarter muscles. During the fast, KIC turnover increased while leucine 
turnover decreased. KIC flux was approximately 10% that of leucine. 
About 40% of KIC and 15% of leucine were oxidized, but they contributed 
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less than 1% of the whole-body COg production. Portal-drained visera 
released KIC and leucine into the periferal blood only in the fed sheep. 
Liver utilized 2 and 12 umol/min of KIC and leucine during both the fed 
and fasted states. Muscle produced leucine and KIC during fasting and 
utilized both during fed states. After fasting leucine going to whole-
body protein synthesis decreased 27%. Hepatic protein synthesis was 
maintained at the expense of muscle during fasting. 
These experiments pointed out several differences in ruminant and 
nonrumlnant BCAA and BCKA metabolism. First, during fasting the 
ruminant liver utilizes leucine, whereas the nonrumlnant liver produces 
leucine. In addition, muscles of the hindquarters produce leucine in 
ruminants, whereas nonrumlnants appear to oxidize leucine in muscle. 
Finally, although the interconversion of KIC and leucine is extensive in 
nonrumlnants, it is limiting in ruminants. 
Leucine and KIC Effects on Protein Metabolism 
In vitro protein turnover studies 
Leucine The first report proposing leucine as a regulator 
of protein metabolism was made in 1971 by Morgan et al. They found that 
in vitro synthesis of whole-heart protein and myosin was increased by 
40% when amino acid concentrations were increased from 1 to 5 times 
normal plasma concentrations, Odessy et al. (1974) later found that 
BCAA inhibited net protein synthesis while increasing the de novo 
synthesis of alanine and glutamlne, which are energy substrates for 
liver, kidney and gut. Another study in the same laboratory reported 
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that leucine Increased protein synthesis and decreased proteolysis in 
muscle under in vitro conditions (Fulks et al., 1975). 
Buse and Reid (1975) also proposed leucine to be a regulator of 
protein turnover as they discovered leucine, but not valine or 
isoleucine, increased protein synthesis in muscle. This effect was not 
blocked by dactinomycin, indicating that the stimulation was at the 
level of previously formed messenger RNA. Furthermore, the injection of 
leucine into fasted rats treated with glucose and insulin increased the 
proportion of polysomes to subunits in ribosomal preparations of psoas 
muscles (Buse et al., 1979). The effect on protein synthesis was 
therefore proposed to be exerted at the level of translation and appears 
to involve peptide chain elongation. Later reports from the same 
laboratory again utilizing rats indicated that BCAA doubled protein 
synthesis in diaphragm muscle, promoted lesser Increases in soleus and 
psoas muscle-protein synthesis and caused no significant increase in 
gastrocnemius and heart muscle-protein synthesis (Buse, 1979). 
Lundholm et al. (1981), using the rectus abdominus muscle from 
humans and the extensor digitorum longus muscle from rats, demonstrated 
that the addition of leucine to the incubation media decreased the rate 
of protein degradation. This was further decreased by the addition of 
other amino acids. In these experiments, insulin Increased protein 
synthesis but did not alter protein degradation. 
Tischler and Goldberg (1980a) found that leucine affects protein 
breakdown in skeletal and cardiac muscle but not in adipose tissue. 
They proposed that the inhibitory effects may be mediated by changes in 
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oxidation-reduction state (Tischler, 1980). Additionally, it has been 
suggested that exogenous BCAA may act as an energy source in muscle and 
slow down amino acid efflux (Freund et al., 1980). 
L-norleucine, L-norvaline, D-norleucine and L-alio-isoleucine were 
found to be as effective as leucine in inhibiting protein degradation, 
but none of these had an effect on protein synthesis (Grinde and 
Seglen, 1981). In this study, KIC did not significantly alter 
proteolysis. 
KIC Although leucine appeared to have a unique role in the 
regulation of protein metabolism, two separate groups postulated that it 
was not leucine, but one of its metabolites, namely KIC, that was the 
active controller of protein metabolism. Chua et al. (1979) were the 
first researchers to suggest that KIC had effects on protein turnover. 
These researchers noted that in rat heart muscle leucine, but not 
isoleucine or valine, inhibited protein degradation and accelerated 
protein synthesis. KIC also decreased proteolysis and increased protein 
synthesis without increasing the intracellular concentration of leucine, 
whereas the keto-acids of isoleucine and valine had no effect on protein 
turnover. Isovalerate also decreased proteolysis and increased protein 
synthesis. Therefore, it was suggested that, although leucine has 
regulatory effects on protein metabolism, its metabolites also possess 
some of these same regulatory effects. 
In perfused rat livers, Poso et al. (1982) found that leucine, 
tyrosine, glutamine, proline, histidine, tryptophan and methionine 
suppressed proteolysis, with leucine being the most potent inhibitor. 
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Leucine decreased proteolysis by 63% when added at 4 to 10 times the 
concentrations normally found in plasma. However, at concentrations 
normally found in plasma, leucine did not decrease proteolysis, whereas 
tyrosine, glutamine, proline, histidine, tryptophan and methionine 
continued to depress proteolysis at normal concentrations. The fact 
that leucine has effects on proteolysis at concentrations higher than 
normal, may have physiological significance because the liver and 
peripheral tissues are exposed to high leucine concentrations after 
feeding when Increased protein synthesis and reduced proteolysis are 
needed for the deposition of the absorbed amino acids. KIC produced 
responses similar to leucine while increasing Intracellular leucine by 
only 7.8%. These researchers noted that, when KIC was added at 4 to 10 
fold times the concentrations normally found in plasma, transamination 
limits interconversion between between leucine and KIC to 4 to 10% of 
total KIC utilization. Additionally, decarboxylation was demonstrated 
to be 10 fold higher than transamination. They concluded that the 
effects of leucine and KIC on hepatic proteolysis are mediated by 
separate pathways. 
Rat diaphragm muscles were found to have increased protein 
synthesis with the addition of .1 mM of leucine (Tischler et al., 1982). 
Protein degradation was not altered until .2 to .5 mM of leucine were 
added. These effects were found in the fed or fasted state, unlike 
leucine inhibition of glucose oxidation which is specific to the fasted 
state (Tischler and Goldberg, 1980a). When leucine transamination was 
inhibited with L-cycloserine, leucine no longer inhibited proteolysis. 
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Additionally, KIC at .5 mM decreased proteolysis without increasing 
protein synthesis. From these three studies, it can be concluded that 
KIC primarily alters protein turnover by lowering proteolysis. 
Although it is debatable as to whether KIC increases muscle protein 
synthesis, KIC has been shown to increase the synthesis of other 
proteins. The rate of albumin synthesis was increased when KIC was 
added to blood perfusing rat livers (Kirsch et al., 1976). In addition, 
a mixture of BCKA increased albumin synthesis per liver weight 
levels when administered intragastrically to rats 16 hr after 
hepatectomy. 
Other examples of BCAA and BCKA altering protein synthesis have 
been reported. Leucine was shown to regulate the secretion of prolactin 
in vitro and increase the release of prolactin from pituitary 
mammotrophs (Cross and Walker, 1984; Miller et al., 1986). A 9-hr 
infusion of BCAA increased the peak frequency of growth hormone 
secretion in baboons (Stewart et al., 1984). KIC has been shown to 
increase insulin release (Panten et al., 1974; Holze and Panten, 1979) 
and proinsulin biosynthesis (Hutton et al., 1980). 
In vivo nitrogen balance 
Leucine Under normal conditions, the liver extensively 
catabolizes aromatic amino acids, methionine and hlstidine. However, 
the liver contributes very little to the catabolism of BCAA. Therefore, 
under normal conditions, BCAA make up 60 to 100% of the amino acids that 
clear the liver (Felig, 1980). However, during chronic liver disease 
with acute exacerbation, aromatic amino acids, methionine, aspartate and 
17 
glutamate are Increased above normal concentrations, whereas BCAA 
concentrations are reduced by 50 to 60% (Sax et al., 1986). 
It would stand to reason, therefore, that the first proposed 
clinical use of BCAA was in the treatment of chronic liver disease 
(Fischer et al., 1975). During liver failure, increased amino acid flow 
through the liver results in these amino acids accumulating at nerve 
endings, replacing the normal transmitters both within the brain and 
peripheral nervous system, which results in nervous system 
abnormalities, encephalopathy and hepatic coma (Fischer and 
Baldessarini, 1971). Additionally, hepatic failure is hypercatabolic. 
Several reports have been published in which BCAA improved liver disease 
and hepatic encephalopathy (Fischer et al., 1976; Higashi et al., 1981; 
Okada et al., 1981; Freund et al., 1982) by providing an energy source, 
decreasing muscle breakdown, increasing hepatic protein synthesis, 
normalizing the plasma and brain amino acid patterns, normalizing 
catecholamine levels and increasing the metabolism of ammonia in 
skeletal muscle (Sax et al., 1986). 
BCAA have also been shown to be useful under conditions of sepsis, 
which is the single highest remaining cause of mortality in surgical 
patients. Sepsis is the pathological state resulting from toxins 
usually produced by microorganisms. During sepsis, muscle breakdown is 
increased as more amino acids are required for energy and synthesis of 
host defense proteins, excessive urea is produced, the liver and other 
organs fail and with this failure the amino acid balance is again 
altered. BCAA treatment would tend to help correct these symptoms (Sax 
18 
et al., 1986). 
Experiments examining other stressful situations have been less 
definitive. There are various problems associated with many of these 
studies including differing levels of stress within an experiment and 
lack of true controls. To briefly summarize these experiments, however, 
BCAA improved nitrogen balance and recovery in several experiments but 
had no effect in others. 
BCAA, administered enterally through a needle-catheter jejunostomy 
to 20 patients, were found to produce positive nitrogen balance within 2 
or 3 days after abdominal surgery (Andrassy et al., 1985). However, 
there were no true controls in this study. Infusion of BCAA to fasted 
and septic rats reduced whole-body nitrogen loss and spared liver 
protein by increasing the fractional synthesis of the liver and muscle 
proteins (Blackburn et al., 1979). Holecek et al. (1985) performed a 
partial (65 to 70%) hepatectomy on rats after which they administered 
either a control solution of amino acids or the same solution plus extra 
BCAA. The onset of DNA synthesis was more rapid in animals fed the 
enriched solutions. When Rigotti et al. (1985) infused rats with 
portalcaval shunts with BCAA, survival was lengthened and neurological 
function was preserved longer. Additionally, BCAA lowered plasma and 
brain ammonia concentrations, while Increasing alanine and glutamine 
concentrations. Ten malnourished cancer patients were provided with 
Isonltrogenous amounts of either a conventional total parenteral 
nutrition diet containing 19% BCAA or a branched-chain amino acid 
enriched diet containing 50% of the amino acids as BCAA (Tayek et al., 
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1986). The BCAA enriched diet increased whole-body leucine flux, 
oxidation and protein synthesis. Protein breakdown and urinary nitrogen 
loss was not altered. 
Severe burns result in highly catabolic states. Initially after a 
burn, there are decreased levels of all amino acids, but in particular, 
BCAA are decreased (Stinnett et al., 1982). However, Snelling et al. 
(1982) did not note a preference for peripheral use of BCAA over 
phenylalanine. Additionally, a 45% BCAA solution did not significantly 
increase nitrogen balance in severely burned rats (Sax et al., 1986). 
Another disease associated with considerable wasting of muscle 
protein is muscular dystrophy. Hudecki et al. (1982) found that twice-
daily injections of BCAA increased righting ability measured by 
standardized flip-test procedure of chickens with muscular dystrophy. 
However, Mendell and co-workers (1982) administered leucine to Duchenne 
muscular dystrophy patients for several months and reported no 
improvements over controls. 
KIC Richards et al. (1967) were the first to suggest the 
use of KIC in a clinical setting. They theorized that ketoacids of 
essential amino acids may be useful in the treatment of uremia by 
reutilizing urea nitrogen for conversion of ketoacids to amino acids, 
lowering blood urea nitrogen levels and increasing protein synthesis. 
Commercial availability of ketoacid compounds limited research of this 
theory. 
The first study using KIC for treatment of uremia was conducted 
several years later by Walser et al. (1973). Ten patients with severe 
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chronic uremia were fed a diet low In protein and sufficient In calories 
plus 6 to 14 g KIC dally for 15-18 days. When KIC-treatment was 
discontinued, plasma urea-nitrogen appearance Increased and nitrogen 
balance decreased. Kampf et al. (1980), Horl et al. (1980) and Attman 
et al. (1984) demonstrated Improvements in uremic conditions when KIC 
was administered. Walser et al. (1983) listed several mechanisms that 
explain why ketoaclds may be used in treating uremia: 1) permitting a 
decrease in nitrogen Intake, 2) decreasing protein breakdown and 3) 
Increasing protein synthesis. 
Several studies were conducted In which KIC was administered to 
patients with severe chronic renal failure. Ell et al. (1978) treated 5 
patients with KIC and reported a decrease in plasma urea concentration, 
urea synthesis and urea excretion plus an Improvement in nitrogen 
balance. Albumin synthesis was also Increased. They concluded that 
this Improvement in nitrogen balance could not be accounted for solely 
by the capture of nonprotein nitrogen by the exogenous KIC. Alverstrand 
et al. (1980), Frohllng et al. (1980) and Kampf et al. (1980) confirmed 
these results by demonstrating increased survival rate and prolonged 
periods of conservative treatments before kidney transplant was 
necessary. Conversely, Hecklng et al. (1980) reported no effect on 
nitrogen metabolism when patients with chronic renal failure were 
treated with KIC. 
When fasting obese subjects were given parenteral Infusions of BCKA 
daily for one week, urinary urea and total nitrogen excretion were 
lowered (Saplr and Walser, 1977). This Improvement continued up to 17 
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days after ketoacld infusion was terminated. Plasma BCAÂ were 
increased, whereas other plasma amino acids were decreased by ketoacid 
treatment. Ketone bodies, free fatty acid, glucose, insulin or glucagon 
concentrations were not affected by treatment. In another study with 
fasted obese men, Mitch et al. (1981) demonstrated that perenteral BCKA 
spared whole-body nitrogen and enhanced muscle bulk. 
The effects of KIC and leucine on nitrogen metabolism in 
postoperative patients were described by Sapir et al. (1983). After 
major abdominal surgery was performed on 21 patients, the only source of 
calories received w^ re 10 g of glucose, 70 mmol of leucine or 70 
mmol of KIC daily (all isocaloric). Whereas leucine had no effect on 
nitrogen balance, 3-methylhistidine excretion and concentrations of 
pre-albumin and pre-retinol-binding protein in plasma, concentrations of 
acetoacetate in plasma were increased. KIC-treated patients had 
improved nitrogen balance, lowered 3-methylhistidine excretion and 
increased plasma pre-albumin, pre-retinol-binding protein and ketone 
bodies. They concluded that KIC, but not leucine, diminishes nitrogen 
wastage in postoperative patients possibly through increased ketosis, 
reduced protein degradation or an effect on liver protein. 
When KIC was administered twice-daily to chickens with muscular 
dystrophy, righting ability was improved, pectoralis major muscle 
mass and protein content was increased and the number of 
degenerating muscle fibers were decreased (Hudecki et al., 1982). 
In a separate trial, patients with Duchenne muscular dystrophy were 
administered KIC orally for four days. During this short experiment. 
22 
protein breakdown was decreased. 
In addition to effects on nitrogen metabolism In these clinical 
trials, KIC was found to also alter phosphorus and calcium metabolism. 
When KIC and other keto acids were administered to patients with chronic 
renal failure or uremia, it was noted that plasma phosphate 
concentrations were decreased (Walser, 1975; Heidland et al., 1978; 
Frohllng et al., 1980; Recking et al., 1980; Kampf et al., 1980; Attman 
et al., 1984). One explanation given for this decrease was that it was 
a result of the anabolic effect of ketoacid treatment. Heidland et al. 
(1978) postulated that the reduced serum phosphate was the result of 
decreased phosphate intake or Increased fecal phosphate excretion due to 
formation of calcium-phosphate complexes in the gut. Another 
explanation for this alteration of phosphorus metabolism may involve the 
reduction in parathyroid hormone concentrations previously reported with 
ketoacid therapy (DlLandro et al., 1982; Schmlcker et al., 1982; 
Lindenau et al., 1982; Barsotti et al., 1982). Although most of these 
studies reported no change in blood calcium, there was one report of 
hypercalcemia due to keto acid infusion (Attman et al., 1984). This 
observation was attributed to increased calcium Intake with 
calcium (KIC)g treatment. 
Effects of KIC on Carbohydrate Metabolism 
Although KIC is considered to be ketogenic, it has been shown 
to interact with carbohydrate metabolism and spare glucose. Chang 
and Goldberg (1978a,b,c; Goldberg and Chang, 1978) reported that 
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leucine provides a significant source of energy to muscle and 
reduces the oxidation of glucose In fasted animals. Infusions of 
leucine in the human forearm have been demonstrated to decrease glucose 
oxidation, resulting in a sparing of glucose (Abumrad et al., 1982a). 
KIC also has been proposed to decrease pyruvate utilization and spare 
glucose (Chang and Goldberg, 1978c; Tischler and Goldberg, 1980a). 
Effects of KIC on Lipid Metabolism 
The pathways of KIC catabolism directly cross the pathways of 
lipid metabolism as KIC can be converted to ketone bodies or 
cholesterol. In 1944, Bloch noted that deuterium-labeled leucine 
was converted to plasma cholesterol. Leucine and KIC are 
obligatorily catabolized to the cholesterol precursor ^ -hydroxy-^ -
methylglutaryl CoA (HMG CoA). However, production of HMG from KIC is 
thought to be a mitochondrial process, whereas cholesterol synthesis 
is a cytosollc process. The most likely mechanism whereby KIC is 
converted to cytosollc HMG starts with the Intramitochondrlal 
oxidation of KIC to HMG CoA, followed by its cleavage via HMG CoA 
lyase to acetoacetate and acetyl CoA. Acetoacetate can enter the 
cytosol and be converted back to HMG CoA via HMG CoA synthetase 
(Mathias et al., 1981). HMG CoA can be enzymatlcally deacylated to 
HMG (Dekker et al., 1958), which is a known competitive inhibitor of 
HMG CoA reductase, a major regulatory enzyme for cholesterol 
synthesis (Flmognarl and Rodwell, 1965; Beg and Lupien, 1972). 
Several studies have demonstrated that oral HMG does decrease 
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cholesterol synthesis and consequently results in lowered 
cholesterol concentrations in tissue and plasma (Beg and Lupien, 
1972; Lupien et al., 1973; Van Niekerk et al., 1984). 
Therefore, it was proposed that the increased plasma leucine 
associated with obesity or diabetes might increase cholesterol 
synthesis and cause the hypercholesterolemia commonly associated 
with these diseases (Paul and Adibi, 1980; Paxton and Harris, 1984). 
There are, however, no reports of dietary leucine altering 
cholesterol metabolism. 
As discussed previously, dietary leucine is catabolized 
primarily in noncholesterol synthesizing tissues (peripheral 
tissues), whereas dietary KIC is catabolized in the gut and liver, 
which are most important in cholesterol synthesis. Thus, dietary 
leucine would be expected to have relatively little effect on 
cholesterol metabolism, whereas dietary KIC would be more likely to 
interact with cholesterol metabolism. 
In an experiment designed to examine the effect of dietary KIC on 
rat cholesterol metabolism, feeding .1% and .5% KIC reduced aortic 
cholesterol concentration 64 and 71% (Flakoll and Nissen, 1986). 
One explanation given for this effect is that HMG produced from KIC 
inhibits HMG CoA reductase activity and cholesterol synthesis. 
However, KIC did not lower plasma cholesterol, whereas HMG does. 
Another mechanism postulated was that KIC may alter the metabolism 
of low-density lipoproteins and high-density lipoproteins, thereby 
changing cholesterol transport and deposition without changing total 
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plasma cholesterol content. Work demonstrating that synthesis of 
the liver-derived plasma protein albumin was increased with addition 
of KIC to liver perfusate (Kirsch et al., 1976) suggests KIC could 
alter lipoprotein metabolism. Finally, KIC can also be converted in 
the cytosol to hydroxy- me thyIbutyrate via KIC oxygenase, which 
has been found to inhibit HMG CoA reductase in vitro (Fimognari and 
Rodwell, 1965). 
Effect of KIC on Hormones 
Hormones that are known to alter and control growth and 
metabolism have been demonstrated to be affected by KIC. Insulin 
secretion has been shown by several researchers to be increased 
by KIC (Grill, 1982; Hutton and Malaisse, 1977; Holze and Panten, 
1979; Stumpf and Kraus, 1978; Biden and Taylor, 1983; Hutton et al., 
1974; Panten et al., 1974; Jain et al., 1978; Zawalich et al., 1978; 
Leclercq-Meyer et al., 1979a, b; Zawalich et al., 1979; Leclercq-
Meyer et al., 1981; Lebrun et al., 1982; Lenzen et al., 1982; Sener 
et al., 1982). Conversely, KIC has been demonstrated to inhibit 
glucagon secretion (Leclercq-Meyer et al,, 1979a, b; Sener et al., 
1982). Stewart et al. (1984) noted that BCAA infusion increased the 
peak frequency of growth hormone release in baboons, whereas Cross 
and Walker (1984) and Miller et al. (1986) reported leucine 
administration to stimulate prolactin synthesis and increase the 
frequency of its release. 
26 
Nutritional Replacement of Leucine by KIC 
Replacing a dietary essential amino acid with its corresponding 
keto acid is not a new concept. The o(-keto analogues of histidine 
(Harrow and Sherwin, 1926) and tryptophan were (Berg et al., 1929; 
Jackson, 1929) found to promote growth in rats fed diets deficient 
in tryptophan. Reports of replacement of other amino acids by 
ketoacid supplementation occurred later (Meister, 1951; Wretlind, 
1953; Cahill and Rudolph, 1942; Bubl and Butts, 1949; Wood and 
Cooley, 1954) 
Several studies with rats examining the efficiency at which KIC 
replaces leucine in the diet have indicated that KIC is about 20 to 25% 
effective at replacing leucine (Chawla and Rudman, 1974; Chow and 
Walser, 1974; Kang and Walser, 1985; Chawla et al., 1975). 
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EXPLANATION OF DISSERTATION FORMAT 
This dissertation is presented in the alternate format, as outlined 
in the Iowa State Graduate College Thesis Manual. Use of the alternate 
format allows for the preparation of independent sections that are 
suitable for submission to scientific journals. 
Three separate papers have been prepared from the data collected 
from research performed to partly fulfill requirements for the Ph.D. 
degree. Each paper is complete in itself and has an abstract, 
introduction, materials and methods, results, discussion, and literature 
cited section. The closeness of the subject matter of the three papers 
allowed a general discussion to be prepared. 
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ANIMAL CARE 
The animals used in the following trials were treated in accordance 
with the Iowa State University animal care guidelines. 
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SECTION I. INFLUENCE OF PARENTERAL AND ORAL ADMINISTRATION OF 
0(-KET0IS0CAPR0ATE ON LAMB GROWTH, FEED CONVERSION AND 
CARCASS COMPOSITION 
Abstract 
Two experiments were conducted to determine if o(-ketoisocaproate 
(KIC), which is thought to be a regulating factor of metabolism, would 
influence lamb growth, feed conversion and nutrient deposition. In the 
first experiment (Exp. 1), daily intraperitoneal injections of a Na-KIC 
solution (-.11 g NaKIC/(kg body weight-d)) increased lamb growth 11% 
(p<.09) above the saline-treated lambs. In the second experiment (Exp. 
2), when 1% Ca (KIC)2 was fed with a soybean meal-supplemented diet 
(SBM), growth was increased 10%, whereas when 1% Ca (KIC)2 was fed with 
a corn gluten meal supplemented diet (CGM), growth was reduced 10% (diet X 
KIC probability of > F - .001). Daily feed intake was reduced 10% when 
KIC was fed with CGM but was not changed when fed with SBM (diet X KIC 
probability of > F - .04). Oral administration of KIC increased wool 
growth irrespective of the diet fed (19% increase, p<.03). Backfat 
thickness was lowered by 28% in Exp. 1 (p<.06) and by 18% in Exp. 2 
(p<.06) with KIC treatment. Fat in the lean tissue was decreased by 16% 
(p<.05) in Exp. 1 with KIC treatment. KIC-treated lambs in Exp. 1 had 
increased bone density (p<.01) and bone mineral density (P<.03). In 
Exp. 1, KIC tended to decrease plasma phosphorus 5% (p<.33). In Exp. 2 
KIC decreased plasma phosphorus 16% when fed with SBM, but did not alter 
plasma phosphorus when fed with CGM (diet X KIC probability of > F -
:05). These data indicate that KIC influences lamb metabolism such that 
parenteral administration improves daily gain and feed conversion and 
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decreases subcutaneous and Intramuscular fat depots, whereas oral 
administration improves daily gain and feed conversion and reduces 
subcutaneous fat when fed with conventional diets, but depresses feed 
intake, daily gain and feed conversion when fed with corn gluten meal, 
which is high in leucine content. 
(Keywords: Sheep, O(|-Ketoisocaproate, Growth, Fat Deposition.) 
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INTRODUCTION 
The o(-keto acid of leucine, O^ k^etoisocaproate (KIC) , has been 
implicated as a regulating factor in metabolism. KIC has been shown in 
vitro to reduce protein breakdown (Chua et al., 1979; Tischler et al., 
1982) and stimulate protein synthesis (Kirsch et al., 1976). Short-
term nitrogen balance studies in humans have demonstrated that KIC 
spares nitrogen under conditions such as injury, starvation or kidney 
malfunctions (Sapir and Walser, 1977; Ell et al., 1978; Sapir et al., 
1983; Attman et al., 1984). In addition to the effects of KIC on 
protein metabolism, it has been reported to inhibit glucagon secretion 
(Leclercq-Meyer et al., 1979; Sener et al., 1982) and stimulate insulin 
secretion (Panten et al., 1974; Holze and Panten, 1979). Either of these 
effects occurring in vivo should favorably affect protein deposition. 
Protein turnover requires a significant expenditure of energy 
(Millward et al., 1975). Therefore, a reduction of proteolysis by KIC 
also should have an energy-sparing effect. The reported sparing of 
glucose by KIC is an example of such energy sparing (Stumpf et al., 
1978). By sparing protein or glucose, KIC administration to meat-
producing animals would minimize catabolism of amino acids and allow 
more energy to be available for increased fat or lean tissue growth. 
Therefore, two experiments were conducted to answer the following 
question; When KIC is administered to growing lambs, which are thought 
to have a relatively high protein catabolism rate, will there be 
increased growth, improved feed conversion and altered nutrient 
deposition in the carcass? 
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MATERIALS AND METHODS 
Experiment 1 
In the first experiment (Exp. 1), medium-frame crossbred rams 
weighing 17 kg were blocked by weight and randomly allotted to either a 
60% corn grain diet (CG, Table 1) or a 30% corn grain plus 30% corn 
gluten feed diet (CGF, Table 1) and intraperitoneal injections of either 
saline or Na-KIC in a 2 X 2 factorial arrangement. Diets were corn-
soybean meal based, balanced with vitamin and trace mineral premixes and 
calculated to be equivalent with respect to metabolizable protein and 
energy. Nine lambs were fed the CG diet, and nine lambs were fed the 
CGF diet. 
Daily intraperitoneal injections were made for approximately 120 
days. After disinfection with iodine, injections were made in the right 
lower abdomen. Nine lambs were injected with 50 ml saline, and nine 
lambs were injected with 50 ml of a NaKIC solution. The concentration 
of NaKIC in the solution was increased in proportion to animal weight 
(-.11 g NaKIC/(kg body weight-d)) with an average of 3.5 g of KIC 
being injected daily (4 to 10% NaKIC solutions). 
The lambs were housed in individual Fiberglas pens, which were 
indoors with light and temperature controlled. Free access to water was 
given with nipple waterers and feed was given twice daily in quantities 
ensuring that feed was available to the lambs at all times. The lambs 
were allowed to adjust to the pens and environment for 2 weeks, during 
which time they were fed the CG diet. 
Gain and feed intake were recorded biweekly. Lamb weights were 
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Exp. 1 Exp. 1 Exp. 2 Exp. 2 
CG* CGF^  SBM° CGM^  
60.00 30.00 48.20 48.20 
- - 20.00 20.00 
30.00 28.50 25.00 -
-
-
- 17.20 
- 30.00 - -
6.70 6.70 5.00 5.00 
.40 .90 - .50 
- 1.00 - 7.30 
1.50 2.00 .88 .88 
.50 - - -
.50 .50 .50 .50 
.10 .10 .10 .10 
-
- .02 .02 
.30 .30 .30 .30 
1.97 1.92 1.86 1.85 
1.33 1.29 1.22 1.20 
12.3 12.9 11.0 10.4 
2.08 2.35 2.01 3.04 
Table 1. Composition of basal diets (% of total mix, as fed) 
Ingredient 
Corn grain ^ 
Dehydrated alfalfa ^ 
Expeller soybean meal 
Corn gluten meal 
Dry corn gluten feed® 
Molasses* sugarcane 
Corn oil 
Corn starch 
Limestone 
Dicalcium phosphate 
Salt  ^
Vitamin A premix . 
Trace mineral premix^  
Ammonium chloride 
Calculated:  ^
Net energy-maintenancg, Meal 
Net energy-gain, Meal 
Metaboliza^ le protein, % 
Leucine. % 
E^xp. 1 diet containing 60% corn grain. 
E^xp. 1 diet containing corn gluten feed. 
"^ Exp. 2 diet containing soybean meal. 
E^xp. 2 diet containing corn gluten meal. 
®20% crude protein. 
S^oy-Plus, West Central Cooperative, Ralston, lA. 
®Dry corn gluten feed, Cargill, Inc., Cedar Rapids, lA. 
M^azola, CPC International Inc., Englewood Cliffs, NJ. 
5^,200,000 lU vitamin A/kg, Hoffmann-LaRoche, Inc., Nutley, NJ. 
^Ca 13-15%; Zn 12%; Mn 8.0%; Fe 10%; Cu 1.5%; I .2%; Co .1%, 
Calcium Carbonate division of J. M. Huber Corporation, Quincy, IL. 
C^alculated from National Research Council values (National 
Research Council, 1982). 
C^alculated from Burroughs et al., 1974. 
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recorded after a 12- to 16-hr fast. Jugular blood samples were taken 
at 4-wk intervals. When a lamb reached 50 kg, it was killed and 
internal organs were dissected, examined, weighed and sampled. 
Longissimus area (LA) at the 12th rib was traced and measured with a 
planimeter. Fat depth at the 12th rib interface was measured. The 
carcasses were physically separated into fat, lean and bone tissues 
with each portion being weighed. The lean tissue was ground through 
a .95-cm die and sampled. To measure fat-free wool growth, the lambs were 
sheared at the start of the trial and after 10 wks of treatment by a 
professional shearer. 
Statistical analyses were performed on the variables from Exp. 1 by 
analysis of variance of the 2X2 factorial model by using the general 
linear models procedure of SAS (1985). Comparisons between treatment 
groups were made by t-test. 
Experiment 2 
Experiment 2 (Exp. 2) consisted of two replicated trials. In the 
first trial, 15 ewes and wethers weighing 29 kg were fed diets 
supplemented with either corn gluten meal or soybean meal and either 0 
or 1% of the diet as Ca (KIC)2 in a 2 X 2 factorial arrangement. In the 
second trial, 21 rams weighing 21 kg were again fed diets supplemented 
with either corn gluten meal or soybean meal and either 0 or 1 % of the 
diet as Ca (KIC)2. 
The lambs were housed, fed and watered as in Exp. 1. The diets 
were isocaloric and equal in metabolizable protein (Table 1). The major 
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difference between the diets was the amino acid composition; the corn 
gluten meal diet was calculated to contain 3.04% leucine, whereas the 
soybean meal diet was calculated to contain 2.01% leucine. 
Experimental protocol for both trials was the same. The lambs were 
weighed and feed intake was recorded every 2 wk. Blood was sampled 
every 3 wk. When a lamb weighed 50 kg, it was killed and internal 
organs were dissected, examined, weighed and sampled. Backfat depth, LA. 
and carcass fat, lean and bone were measured as in Exp. 1. Wool growth 
was measured by clipping a known marked area on each side of each lamb 
both at the start and at the conclusion of the trials. 
Statistical analyses were performed on the variables from the 
experiment by analysis of variance of the replicated 2X2 factorial 
model by using the general linear models procedure of SAS (1985) and 
examining the effect of KIC, diet and KIC X diet interaction. Because 
there were no significant interactions between the trials and treatments 
(that is, the variables measured consistently followed the same trends 
in both trials), the results will be reported as the means of both 
trials. 
Analytical Methods 
Materials Na-KIC and Ca (KIC)g were obtained from SOBAC (336 Rue 
Saint-Honore, 75001, Paris, France). 
Soft tissue analysis Fat and moisture were determined on the 
meat samples by using Goldfish extraction and lyophilization, 
respectively, according to AOAC procedures (AGAC, 1975). Crude protein 
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Tecator Kjeltec System 1003 distilling unit. 
Wool analysis After an initial weighing, wool was rinsed with 
water to remove dirt and debris, dried at 60° C and reweighed. The 
wool was then rinsed with chloroform to extract fat, dried at 60° C and 
reweighed to obtain a fat-free wool weight. 
Bone Analysis The humerus was dissected from the lambs in Exp. 
1, and a 5.OS-cm section from the exact center of the bone was removed, 
stripped of connective tissue and marrow and was measured for volume via 
planimeter tracing. The sample was weighed, dried at 80° C and 
reweighed. Bone density was calculated as the dried sample weight 
divided by the sample volume. The bone sample was ashed in a muffle 
furnace at 600° C and weighed to obtain ash weight. Ash density was 
calculated as the sample ash weight divided by the sample volume. 
Plasma metabolite analysis Plasma leucine and KIC were 
analyzed by adding 20 nmol o(-ketocaproate (KG) and 150 nmol norleucine 
(NL) as internal standards to 1 ml plasma. After deproteinizing with 
,75 N perchlorate and separation of amino and keto acids via cation 
column (Nissen et al., 1982), the extracts were dried under nitrogen gas 
and derivatized with 100 ul pyridine plus 100 ul N-methyl-N (t-butyl-
dimethylsilyl) trifluoroacetamide containing 1% t-butyldimethyl-
chlorosilane (Regis Chemical Company, Morton Grove, IL). KIC and KG 
were monitored at 301 AMU, and leucine and NL were monitored at 302 AMU 
by using a gas chromatography-mass spectrometry system (Hewlett-Packard 
5970A). Concentrations were calculated by comparing the KIC to KG 
ratios and leucine to NL ratios with that of the standards. 
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An automated system (Rotochem IIA, Travenol Laboratories, 
Deerfield, IL) was used with enzymatic and colorimetric kits for 
determination of plasma glucose (Glucose (HK) Reagent, Gilford Systems, 
Oberlin, OH), blood urea nitrogen (BUN; BUN Reagent, Gilford Systems, 
Oberlin, OH), albumin (SpecTru BCG Albumin Reagent, Pierce Chemical 
Company, Rockford, IL), calcium (Rotochem Calcium, Pierce Chemical 
Company, Rockford, IL), and phosphorus (Worthington Inorganic Phosphorus 
Reagent Set, Cooper Biomedical, Inc., Malvern, PA). Because plasma from 
Exp. 1 and Trial 2 in Exp. 2 was collected into tubes with EDTA, calcium 
values from these trials were not reported. 
Plasma hormone analysts Plasma was analyzed for Cortisol 
concentration by radioimmunoassay (Amerlex Cortisol Kit, Amersham 
Corporation, Arlington Heights, IL). Plasma growth hormone and insulin 
concentrations were determined by radioimmunoassay by using bovine 
growth hormone antibody and bovine insulin antibody, respectively 
(Trenkle, 1972). 
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RESULTS 
The effect of KIC on lamb performance in Exp. 1 is reported in 
Table 2. When KIC was delivered intraperitoneally, lamb growth was 
improved 11% above the control (p<.09). Neither daily feed intake nor 
feed conversion were altered by KIC treatment. Intraperitoneal doses of 
KIC reduced wool growth by 14% (p<.09). 
Lamb performance in Exp. 2 is reported in Table 3. When 1% KIC was 
fed with the CGM-supplemented diet, daily gain was reduced 12%, whereas, 
when 1% KIC was fed with the SBM-supplemented diet, daily gain was 
increased 10% (diet X KIC probability of > F - .001). Daily feed intake 
was reduced 10% when KIC was fed with CGM, but was not changed when fed 
with SBM (diet X KIC probability of > F - .04). KIC depressed feed 
conversion by 4% when fed with CGM, whereas it improved feed conversion 
by 9% when fed with SBM (diet X KIC probability of > F - .02). Oral 
administration of KIC increased wool growth irrespective of the diet fed 
(19% increase, p<.03). 
Lamb organ weight in Exp. 1 is reported in Table 4. When expressed 
as percentage of body weight, no change in carcass, liver, spleen, lungs 
or adrenal glands were noted. The weight of the heart and kidneys were 
increased 12% (p<.01) and 11% (p<.07), respectively. Lamb organ weight 
in Exp. 2 is reported in Table 5. When expressed as percentage of body 
weight, no change in carcass, liver, spleen, heart, lungs, adrenal 
glands or kidneys were noted. 
The effects of intraperitoneal administration of KIC on lamb 
carcass composition are reported in Table 6. Perirenal fat and lA were 
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Table 2. Effects of daily intraperitoneal injections of 
o^ -ketoisocaproate (KIC) for approximately 120 days on lamb 
growth, feed conversion and wool growth (Exp. 1) 
Parameter Saline KIC SEM* P<^  
n 9 9 
Daily gain, g 293 324 12 .09 
Daily intake, g 1330 1400 32 .15 
Feed/gain 4.60 4.36 .17 .66 
Fat-free wool gain 
mg/(cm2'd) .81 .70 .05 .08 
P^ooled standard error of the mean. 
b Probability that treatment means are not different. 
Table 3. Effects of oral administration of A^ ketoisocaproate (KIC) on 
growth, feed conversion and wool growth of lambs fed diets 
supplemented with corn gluten meal (CGM) or soybean meal (SBM; 
Exp. 2, Trials 1 and 2 combined) 
—Supplement (Suppl) 
- - - CGM" - - - - - - - SBM" "" 
% Dietary KIC Suppl 
Parameter 0 10 1 SEM^  Suppl KIC x KIC 
n 9 9 10 8 
Daily gain, g 349 306 315 346 10 .71 .59 .001 
Daily intake, g 1570 1430 1530 1520 32 .24 .04 .04 
Feed/gain 4.50 4.68 4.87 4.41 .13 .58 .31 .02 
Fat-free wool gain, 
mg/(cm2'd) .96 1.06 .87 1.11 .07 .62 .03 .42 
P^ooled standard error of the mean. 
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Table 4. Effects of daily intraperitoneal injections of 
drketoisocaproate (KIC) for approximately 120 days on lamb 
organ weight (Exp. 1) 
Parameter Saline KIC SEN* P<^  
Final weight, kg 48.8 48.6 .2 .64 
Carcass, 52.0 52.5 .8 .60 
Liver, 2.0 2.2 .1 .13 
Spleen, %° .25 .25 .02 .93 
Heart, .40 .45 .01 .02 
Lungs, %° 1.10 1.07 .07 .80 
Kidneys, %° .31 .34 .01 .07 
Adrenal glands, X 1000 7.0 6.8 .1 .65 
^Pooled standard error of the mean. 
^Probability that treatment means are not different. 
^Percentage of final body weight. 
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Table 5. Effects of oral administration of o<,-ketoisocaproate (KIC) on 
organ weight of lambs fed diets supplemented with corn gluten 
corn gluten meal (CGM) or soybean meal (SBM; Exp. 2, Trials 1 
and 2 combined) 
Supplement (Suppl)— 
- - -CGM""-- - - - -SBM-- - -P > F 
supp: 
Parameter 0 1 0 1 SEM® Suppl KIC X KIC 
Final weight, kg 49.7 48.6 48.3 50.2 .7 .72 .53 .03 
Carcass, 55.5 55.2 55.3 55.2 .8 .80 .79 .95 
Liver, 2.1 1.9 1.9 1.9 .1 .22 .22 .28 
Spleen, .17 .21 .17 .17 .01 .15 .22 .24 
Heart, .39 .39 .40 .41 .01 .35 .73 .80 
Lungs, .83 .92 .96 .91 .05 .30 .65 .16 
Kidneys, .31 .29 .29 .31 .01 .65 .97 .14 
Adrenal , 
glands, % X 1000 5.4 4.7 5.6 5.2 .3 .53 .26 .75 
P^ooled standard error of the mean. 
P^ercentage of final body weight. 
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Table 6. Effects of daily intraperitoneal injections of 
o^ -ketoisocaproate (KIC) for approximately 120 days on lamb 
carcass composition (Exp. 1) 
Parameter Saline KIC s EM® P<^  
2 Longissimus area, cm 15.2 14.8 .8 .78 
Backfat, mm 5,3 3.8 .5 .06 
Perirenal fat, 1.5 1.3 .2 .52 
Carcass ; 
Separable lean, 55.2 53.0 .9 .12 
Separable fat, 18.9 17.9 1.2 .55 
Separable bone, 24.4 25.7 .9 .67 
Lean; 
Dry matter, 30.9 29.0 .8 .10 
Crude protein, 16.8 17.1 .5 .63 
Ether extract, 14.0 11.7 .8 .05 
Wool fat, 5.5 4.1 .9 .30 
Bone (humerus): 
Dry matter, %® 86.8 86.5 .3 .53 
Ash, %® 59.4 58.9 .3 .20 
Density , g/cm 1.35 1.47 .03 .01 
i 3 Ash densitv . e/cm .92 o
 
o
 
.02 .03 
P^ooled standard error of the mean. 
Probability that treatment means are not different. 
P^ercentage of final body weight. 
Percentage of carcass weight. 
P^ercentage of lean tissue weight. 
Percentage of wool weight. 
P^ercentage of bone weight. 
D^ried humerus sample weight divided by the sample volume. 
Ashed humerus sample weight divided by the sample volume. 
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not altered by KIC treatment. Backfat thickness was lowered with KIC 
treatment by 28% (p<.06). The portions of the carcass separated into 
lean, fat or bone were not significantly altered. Fat in the lean 
tissue was decreased by 16% with KIC (p<.05). Wool fat was not 
significantly altered. Bone tissue dry-matter and ash content were not 
altered by KIC treatment, but KIC increased bone density 9% (p<.01) 
and bone mineral density 9% (p<,03). 
The effects of oral administration of KIC on lamb carcass 
composition are reported in Table 7. KIC treatment did not alter LA. 
Perirenal fat was not altered by KIC treatment, but there was more 
perirenal fat for animals fed the SBM diet when compared with the CGM 
diet (p<.008). Backfat thickness was lowered by KIC for both diets (18% 
decrease, p<.06). The portions of the carcass separated into fat, lean 
or bone were not significantly altered by treatment. Fat in lean tissue 
and wool was not significantly altered by KIC. 
Plasma parameters from lambs in Exp. 1 are reported in Table 8. 
Plasma KIC in the KIC-treated lambs was 31% lower than in the control 
lambs (p<.03). No significant changes in plasma leucine, glucose, BUN, 
albumin or phosphorus concentrations as a result of KIC treatment were 
noted. In addition, plasma concentrations of Cortisol, growth hormone 
or insulin were not altered. 
Plasma parameters from lambs in Exp. 2 are reported in Table 9. 
Plasma phosphorus was decreased 16% when lambs were fed KIC with the SBM 
diet, whereas KIC did not affect plasma phosphorus when fed with the CGM 
diet (diet X KIC probability of > F - .05). No significant changes in 
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Table 7. Effects of oral administration of 0(-ketoisocaproate (KIC) on 
carcass composition of lambs fed diets supplemented with corn 
gluten meal (CGM) or soybean meal (SBM; Exp. 2, Trials 1 and 
2 combined) 
—Supplement (Suppl)— 
- - - CGM" - " " - - - - SBM" "*• 
% Dietary KIC Suppl 
Parameter 0 10 1 SEM^  Suppl KIC x KIC 
Longissimus area,cm ^14.9 15.5 15.4 14.6 .6 .78 .94 .23 
Back fat, mm 6.3 4.9 6.1 5.4 .5 .82 .06 .49 
Perirenal fat, 1.80 1.34 2.11 2.03 .21 .008 .24 .33 
Carcass: 
Separable lean, 50.7 51.0 51.1 50.8 1.2 .94 .98 .83 
Separable fat, %° 25.8 26.3 27.2 25.9 1.3 .65 .78 .51 
Separable bone, %° 23.5 22.7 21.7 23.3 .9 .43 .64 .19 
Lean: 
Dry matter, 31.1 30.7 30.8 30.0 .7 .54 .44 .77 
Crude protein, 18.5 19.1 18.7 18.0 .32 .15 .77 .06 
Ether extract, 15.4 16.3 17.0 16.7 .75 .32 .77 .37 
Wool fat, 21.5 19.8 21.0 20.6 1.5 .82 .51 .65 
P^ooled standard error of the mean. 
P^ercentage of final body weight. 
P^ercentage of carcass weight. 
'^ Percentage of lean tissue weight. 
P^ercentage of wool weight. 
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Table 8. Effects of daily intraperitoneal injection of 
o^ -ketoisocaproate (KIC) for approximately 120 days on lamb 
plasma parameters (Exp. 1) 
Parameter Saline KIC SEM^  P<° 
KIC, uM 25.4 17.4 2.4 .03 
Leucine, uM 249 242 15 .74 
Glucose, mg/dl 76.9 74.9 2.5 .58 
BUN, mg/dl 31.1 30.0 1.2 .53 
Albumin, mg/dl 4.00 4.06 .08 .55 
Phosphorus, mg/dl 10.1 9.6 .3 .33 
Cortisol, ug/dl 1.26 1.34 .20 .78 
Growth hormone, ng/ml 2.83 3.49 .59 .55 
Insulin, ng/ml 0.76 0.68 .17 .71 
B^lood was sampled after an overnight fast and pooled for analysis. 
P^ooled standard error of the mean. 
P^robability that treatment means are not different. 
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Table 9. Effects of oral administration of o(-ketoisocaproate (KIC) on 
blood parameters of lambs fed diets supplemented with corn 
gluten meal (CGM) or soybean meal (SBM; Exp. 2, Trials 1 and 2 
combined) 
—Supplement (Suppl)— 
---CGM"--- ----SBM""" -------p ^  F-----
% Dietary KIC , Suppl 
Parameter 0 10 1 S EM Suppl KIC x KIC 
KIC, uM 22.2 19.6 18.7 26.2 3.8 .65 .51 .19 
Leucine, uM 347 317 237 231 20 .0001 .37 .60 
Glucose, mg/dl 79.1 77.6 81.0 77.6 3.2 .77 .54 .77 
BUN, mg/dl 28.6 25.3 26.7 24.4 2.1 .52 .20 .81 
Albumin, mg/dl 3.81 3.87 3.96 3.58 .16 .66 .66 .18 
Calcium, mg/dl° 10.7 10.8 10.9 11.1 .2 .30 .55 .96 
Phosphorus, mg/dl 7.9 7.9 8.5 7.1 .3 .78 .06 .05 
Cortisol, ug/dl 2.91 1.76 2.35 2.79 .47 .67 .46 .11 
Growth hormone, ng/ml 1.01 1.69 1.26 1.32 .34 .85 .29 .37 
Insulin, ng/ml 2.00 1.02 0.87 0.88 .24 .02 .06 .05 
*Blood was sampled after 4 and 6 weeks of treatment after an 
overnight fast. 
P^ooled standard error of the mean. 
V^alues are from Trial 1 only. 
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plasma KIC, leucine, glucose, BUN, albumin or calcium concentrations 
with KIC treatment were noted. However, plasma leucine concentration 
was increased 29% for lambs fed the CGM-supplemented diet (p<.0001). 
Plasma concentrations of Cortisol or growth hormone were not altered. 
Although KIC had no effect on plasma insulin concentration in lambs fed 
the SBM diet, insulin was decreased 49% when KIC was fed with the CGM 
diet (diet X KIC interaction probability of > F - .05). Insulin 
concentration in the lambs fed the CGM diets were 42% higher than in the 
lambs fed the SBM diets (p<.02). 
Discussion 
KIC improved lamb gain and feed conversion in all experiments when 
fed with diets in which soybean meal was the supplemental source of 
protein. Overall gain was increased slightly more than 10%, whereas 
feed conversion was improved approximately 8%. Additionally, KIC 
reduced disposition of energy to internal and external fat depots. 
Backfat, renal fat, dissectible carcass fat and fat in the carcass lean 
tissue were all lower on KIC treatments. Together, these data suggest 
that KIC improves growth by decreasing fat synthesis and increasing 
protein synthesis. 
The most likely mechanism for the effects of KIC points to its 
interaction with protein turnover. It has been estimated that 4 ATP of 
energy are required per peptide bond synthesized. Because protein 
turnover is an energy-requiring process, the energy expenditure of an 
animal can be significantly influenced by changes in protein metabolism 
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(Reeds et al., 1985). This is particularly true in ruminants, in which 
a larger protein mass has to be maintained and considerably more of the 
body weight consists of digestive tissue, which, when compared with 
other tissues, has a comparatively high rate of protein turnover. The 
energy cost of protein synthesis has been shown to be greater in 
ruminating than in nonruminating lambs (Rattray and Jagusch, 1977). 
Although Waterlow et al. (1978) estimated that protein synthesis made up 
10 to 20% of total heat production in mature nonruminants, Davis et al. 
(1981) estimated that the energy cost of protein synthesis accounted for 
42% of daily heat production in growing lambs. The rate of protein 
synthesis is approximately 20 fold that of protein deposition (Waterlow 
et al., 1978). Therefore, a small decrease in proteolysis because of 
KIC could result in a significant gain in protein deposition. 
Additionally, with decreased proteolysis, fewer free amino acids 
would be available to be catabolized for energy use and other sources of 
energy (lipid and glucose) would have to be utilized. But previous 
studies have shown that glucose is also spared by KIC (Tischler and 
Goldberg, 1980). Therefore, more fats may need to be utilized as energy 
sources, and less would be stored. 
Whether the alterations in fat deposition is a result of a direct 
or indirect effect of KIC on adipose tissue metabolism is unclear. In a 
study in which KIC was fed to lactating dairy cows, increased milk fat 
production was attributed to an increase in de novo fatty acid 
synthesis by the mammary gland and an increase in transport of blood 
lipids to the mammary gland (VandeHaar et al., 1988). 
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Another possible mechanism could be through altered hormone or 
hormone receptor activity. No differences in Cortisol or growth hormone 
concentrations were noted in the experiments reported here, but blood 
was sampled only at one point in time and these hormones have been shown 
to be secreted episodically and at different rates as time from feeding, 
stress or other environmental circumstances change. 
Insulin was not altered by KIC in Exp. 1, nor when fed with the SBM 
diet in Exp. 2. However, when KIC was fed with the COM diet in Exp. 2, 
insulin levels were decreased. Therefore, when KIC increased growth 
rates of the lambs, insulin levels were not altered, but when KIC 
decreased growth, insulin levels were decreased. While KIC has been 
demonstrated to stimulate insulin secretion (Panten et al., 1974; Holze 
and Panten, 1979; Leclercq-Meyer et al., 1979; Sener et al., 1982), 
there are other reports in which a KIC load did not alter Insulin 
concentration in dogs (Abumrad et al., 1982b) or humans (Sapir et al., 
1983). Previous research has demonstrated leucine administration raises 
plasma insulin levels (Abumrad et al., 1982a), which is consistent with 
the results of feeding the CGM diet in Exp. 2. But the mechanism 
whereby KIC would decrease insulin levels under these conditions is 
unclear. 
It could be argued that the growth response to KIC may be through a 
ruminai effect on microorganisms as has been shown with other short-
chain fatty acids. Although in vitro results indicate that rumen 
microorganisms have requirements for branched-chain acids and that 
branched-chain acid supplementation Increases rumen microorganism growth 
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(Socransky et al., 1964; Bryant, 1974; Allison, 1978), minimal or no 
increase in growth was observed in studies in which branched-chain acids 
were fed to ruminants (Hungate and Dyer, 1956; McCollum et al., 1986). 
Additionally, as perenteral KIC gave responses similar to oral KIC, KIC 
promoting growth through rumen microorganisms seems unlikely. However, 
a direct effect of KIC on intestinal and hepatic tissue metabolism 
cannot be discounted. 
Whereas the structure and metabolic fate of KIC and leucine are 
similar, suggesting that KIC and leucine may produce similar 
physiological responses, it is unlikely that KIC acts through leucine. 
Although KIC has been implicated in altering nitrogen metabolism, its amino 
acid leucine has not exhibited many of these properties. The reduction 
of proteolysis by KIC is not mimicked by leucine when transamination is 
prevented (Chua et al., 1979; Tischler et al., 1982, Poso et al., 1982). 
When KIC infusions were given to postoperative patients on no other 
source of calories, proteolysis was suppressed, and the postoperative 
fall in plasma levels of pre-albumin and retinol-binding protein seen in 
controls was significantly reduced (Sapir et al., 1983). No response 
was observed with leucine infusions. Herlong et al. (1980) observed 
significant improvement in grade of encephalopathy, electroencephalo-
graphic abnormalities and hyperammonaemia when ornithine salts of 
branched-chain keto acids were administered orally for 5 days to 
encephalopathic patients. Significantly lesser effects were observed in 
similar patients treated with branched-chain amino acids. Nitrogen was 
significantly spared in fasted obese men infused with KIC when compared 
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with controls or leucine-infused treatments (Mitch et al., 1981). 
Although it is unlikely that KIC acts through leucine, it is 
unclear whether KIC acts through any of its breakdown products. Both 
ketone bodies (Sherwin et al., 1975) and isovalerate (Chua et al,, 1979) 
have been shown to decrease proteolysis. 
Oral doses of KIC increased wool growth, irrespective of the diet 
fed, whereas KIC decreased wool growth when delivered intraperitoneally, 
irrespective of the diet fed. This may be a reflection of the site of 
KIC metabolism. An oral dose would undergo extensive ruminai 
degradation, considerable splanchnic uptake, with a small amount of KIC 
reaching the periphery. It has been demonstrated in dogs that 85% of an 
oral dose of KIC is metabolized by the splanchnic tissues (Abumrad et 
al., 1982b; Bassler and Pietrek, 1983). Much more of an intraperitoneal 
load of KIC would reach the peripheral tissues. Peripheral uptake of 
KIC has been shown to be rapid and extensive (Pozefsky and Walser, 1977; 
Bassler and Pietrek, 1983). In the present experiments, daily doses of 
3 g of KIC intraperitoneally and 15 g of KIC orally with a diet not 
excessive in leucine produced equivalent responses in gain. 
Bone in the carcass seemed to increase when KIC was injected or 
fed with the SBM-supplemented diet. In addition, bone density (Exp. 1) 
was increased by KIC. In Exp. 2, blood calcium was not changed, but 
blood phosphorus was decreased. Therefore, the blood calcium to 
phosphorus ratio was increased. When KIC and other keto acids were 
administered to patients with chronic renal failure or uremia, it was 
noted that plasma phosphate concentrations were decreased (Walser, 1975; 
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Heldland et al., 1978; Frohling et al., 1980; Hecklng et al., 1980; 
Kampf et al., 1980; Attman et al., 1984). One explanation given was 
that this decrease was the result of the anabolic effect of the ketoacid 
treatment. Heidland et al. (1978) postulated that the reduced serum 
phosphate was the result of decreased phosphate intake or increased 
fecal phosphate excretion because of formation of calcium-phosphate 
complexes in the gut. This alteration of phosphorus metabolism may 
involve the reduction in parathyroid concentrations. There several 
previous reports of parathyroid concentration decreasing during ketoacid 
therapy (DiLandro et al., 1982; Schmicker et al., 1982; Lindenau et al., 
1982; Barsotti et al., 1982). Although most clinical studies reported 
no change in blood calcium, there was one report of hypercalcemia due to 
keto acid infusion (Attman et al., 1984). The reason for this 
observation was attributed to increased calcium intake with Ca (KIC)2 
treatment. There were not any differences in blood calcium reported 
when Ca (KIC)2 was fed in Exp. 2, but the amount of calcium fed was 
maintained constant between treatments. 
Although leucine and KIC are catabolized through the identical 
biochemical pathway, the organs by which they are metabolized are 
distinctly different. The liver is limiting in branched-chain amino 
acid transaminase, so very little dietary leucine is catabolized until 
it reaches extrahepatic tissues (Ichihara and Koyama, 1966; Krebs and 
Lund, 1977). Conversely, the liver contains abundant quantities of 
branched-chain ketoacid dehydrogenase (Shinnick and Harper, 1976), the 
enzyme responsible for the first irreversible step of KIC oxidation. 
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Lambs that received the CGM-supplemented diet had significantly 
higher blood concentrations of leucine than did the lambs receiving the 
SBM-supplemented diet. The ruminant species may be more responsive to 
dietary leucine in terms of blood leucine concentration because of 
reduced transamination when compared with other species of animals 
(Nissen and Ostaszewski, 1985; Pell et al., 1986). Another difference 
between lambs on the SBM and CGM diets were the lowered amount of renal 
fat for lambs fed the CGM diet. The reasons for this are unclear. 
When KIC was fed with SBM, feed intake was not affected. However, 
when KIC was fed with CGM, feed intake was significantly reduced by 10%, 
suggesting a negative interaction of KIC with high leucine dietary 
intake. The lowered intake was reflected in lamb gain, which was 
reduced 12% when KIC was fed with CGM. Conversely, when KIC was fed with 
SBM, gain was significantly increased 12%. In addition, when fed with 
CGM, KIC worsened feed conversion by 6%, but when fed with SBM, KIC 
improved feed conversion by 9%. 
In conclusion, the increased growth and decreased fat deposition in 
lambs administered KIC suggests that KIC may alter energy partition 
between fat and lean tissue, possibly through its control of protein 
metabolism. Feeding KIC improves performance and alters carcass 
composition of lambs similarly to injecting KIC when KIC is fed with 
diets not excessive in leucine (conventional lamb diets). These data 
demonstrate that increased rate of growth, reduced disposition of energy 
to internal and external fat depots and increased bone density are 
achieved by administering KIC to growing lambs. 
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SECTION II. INFLUENCE OF FEEDING o(-KETOISOCAPROATE PROTECTED FROM 
RUMINAI DEGRADATION ON GROWTH, FEED CONVERSION AND CARCASS 
COMPOSITION IN STEERS AND LAMBS 
Abstract 
Two experiments were conducted to examine if feeding 
O^ ketoisocaproate (KIC) protected from ruminai degradation would alter 
gain, feed conversion or carcass composition of cattle and sheep. In 
Experiment 1 (Exp. 1), 72 steers in 12 pens were fed a basal diet plus 
either 0, .02, .07 or .2% Ca(KIC)2. Experiment 2 (Exp. 2) consisted of 
two replicated trials in which lambs were fed .05% leucine (n-12), KIC 
(n-16), isovalerate (IVA; n-12) or limestone (control; n-13). In both 
experiments, treatment supplements were combined with zein, and pellets 
were formed that were resistant to ruminai degradation. Over the 161-d 
Exp. 1, cattle growth was increased in quadratic dose-responsive manner 
(p<,03) with .02% KIC increasing gain by 14%. The number of cattle 
grading choice or prime was increased linearly by KIC (p<.02). Cattle 
plasma glucose, glucagon and Cortisol were linearly decreased by KIC 
(p<.02, p<.09 and p<.02, respectively), whereas insulin/glucagon was 
linearly increased (p<.06). Compared with controls, KIC decreased lamb 
backfat 17% (p<.04) and increased weights of psoas 11% (p<.07), 
longissimus 8% (p<.05), gastrocnemius 12% (p<,07), tibia 5% (p<.09) and 
humerus 12% (p<.006). Leucine increased weights of tibia 5% (p<.08) and 
humerus 10% (p<.06). Supplemental KIC, protected from ruminai 
degradation, has potential to improve cattle and lamb growth and alter 
body composition at doses 10-to-20 fold lower than when fed unprotected. 
Keywords: Sheep, Cattle, 0(-Ketoisocaproate, Growth, Carcass composition. 
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INTRODUCTION 
Previous research has demonstrated that a&ketisocaproate (KIC) 
administered to lambs intraperitoneally at 3 g daily or orally at 15 g 
daily improved improved gain and feed conversion approximately 10% 
(Flakoll and Nissen, 1986; Flakoll et al., 1986). Additionally, 
internal fat and backfat depots were reduced by KIC treatment in these 
lambs. KIC also has been shown to increase milk fat production in dairy 
cattle (VandeHaar et al., 1988). In these trials, intraperitoneal doses 
of KIC were found to have equivalent growth-promoting effects at a dose 
one-fifth that of oral trials. Similar to free amino acids, KIC is 
readily degraded in the rumen. Therefore, if KIC-ruminal loss is 
reduced, the dose required to produce positive growth effects would be 
reduced. 
Several methods have been proposed to protect compounds from 
ruminai degradation. These include lipid encapsulation (Smith and 
Boling, 1984), coating with blood meal (Mir et al., 1984), coating with 
fish hydrolysate (Mir et al., 1984) and encapsulation with a styrene 
and 2-methyl-5-pyridine copolymer (Dannelly and Ardell, 1980a, b; Papas 
et al., 1984). However, these methods are not optimal in that they do 
not result in optimal by-pass, nor are they available for small-scale 
production. Therefore, a new technique was developed, whereby the 
rumen-stable protein zein, was combined with KIC and other metabolites 
and formed into pellets. Approximately 60% of KIC and methionine were 
estimated to bypass the rumen with this technique (VandeHaar et al., 
1987). 
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Therefore, the objective of this research was to answer the 
following questions; 1) does oral administration of KIC, protected from 
ruminai degradation, alter steer and lamb growth rates and carcass 
composition as effectively as intraperitoneal or unprotected oral 
administration; 2) will the optimal dose for these effects be lower than 
for intraperitoneal or unprotected oral administration; 3) do leucine, 
KIC and isovalerate (IVA) invoke similar responses; and 4) is the effect 
of KIC mediated by changes in growth regulating hormones, such as 
insulin and glucagon for which secretion is known to be altered by KIC 
(Leclercq-Meyer et al., 1979; Panten et al., 1974; Holze and Panten, 
1979; and Sener et al., 1982)? 
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MATERIALS AND METHODS 
Experiment 1 
In the first experiment (Exp. 1), 72 medium-frame cross-bred 
steers, with an average weight of 263 kg, were blocked by weight and 
allotted to 12 pens of 6 animals each. Three pens were assigned to each 
treatment. A basal diet consisting of mainly corn and soybean meal was 
fed ad libitum to all cattle (Table 1). The diet was high in energy and 
protein to maintain a high level of growth. The treatments consisted of 
four levels of Ca (KIC)2 in a pelleted supplement (Table 2): 0%, .02%, 
,07% and .20% of the basal diet as KIC (.05% control pellets, ,05% KIC 
pellets, .175% KIC pellets and .50% KIC pellets). The pellets were 
prewelghed and top-dressed on the basal diet twice daily. After 72 d, 
the cattle on the .20% KIC treatment were removed from the experiment. 
Neither Implanted growth promotants nor lonophores were Included in 
this study. The cattle were placed in the feedlot and fed a growing 
ration for 5 wk prior to the start of the experiment. Weights were 
recorded on 2 consecutive d at the beginning and end of the experiment, 
and every 14 d during the trial. Jugular blood samples were collected 
into sodium EDTA-coated tubes and centrifuged. Plasma was stored at -
-70° C. 
The cattle were sold as one complete group to a commercial beef 
processing plant when they were appraised by visual examination to grade 
Choice. Longlsslmus area and fat thickness over the longlsslmus at the 
13th rib were measured on each carcass. Quality and yield grades and 
the percentage of perirenal, pericardial and pelvic fat were estimated 
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Table 1. Composition of basal diets for steers 
mix, as fed) 
in Exp. 1 (% of total 
Ingredient 
(• 
0-72 Days 
-263-378 kg) 
72-161 Days 
(-378-485 kg) 
Corn grain 48.9 54.3 
Corn cobs 24.4 24.4 
Expeller soybean meal* 17.8 12.8 
Molasses, sugarcane 7.0 7.0 
Limestone 1.3 1.3 
Dicalcium phosphate .25 .25 
Salt .2 .2 
Trace mineral premix^  .02 .02 
Vitamin A premix° .1 .1 
Calculated: 
Dry matter, %^  88 88 
Crude protein, %^  15 13 
Metabolizable protein, g/kg® 86 76 
Leucine, %^  1.7 1.7 
Net energy-  ^
maintenance, Mcal/kg 1.7 1.7 
gain, Mcal/kg*^  1.1 1.1 
fsoy-Plus, West Central Cooperative, Ralston, lA. 
Ca, 13-15%; Zn 12%; Mn 8.0%; Fe 10%; Cu 1.5%; I .2%; Co .1%; 
Calcium Carbonate division of J. M. Huber Corporation, Quincy, IL. 
5^,200,000 lU Vitamin A/kg, Hoffmann-LaRoche, Inc., Nutley, NJ. 
Calculated from National Research Council values (1982). 
C^alculated from Burroughs et al. (1974). 
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Table 2. Composition of treatment supplements in Exp. 1 and 2* 
Ingredient Leucine KIC IVA Control 
g/kg 
Zeirf 450 450 450 450 
Ethanol 278 278 278 278 
Water 37 37 37 37 
Limestone,^  16 10 8 45 
Sodium Bentonite,^  5 5 5 10 
Leucine® 
D^ Ketoisocaproate^  
Isovalerate® 
340 
400 
420 
D^ried treatment pellets contained approximately 2.5 mole leucine, 
KIC or IVA, and 64, 91, 97 or 180 g calcium per kg leucine, KIC, IVA 
or control pellets, respectively. 
F^reeman Industries, Tuckahoe, NY. 
°325 mesh; Iowa Limestone Company, Des Moines, lA. 
2^00 mesh; American Colloid Company, West Des Moines, lA. 
®Sigma Chemical Company, St. Louis, MO. 
C^a (dfketoisocaproateXg HgO; SOBAC, Rue Saint-Honore, 75001, 
Paris, France. 
®Ca (isovalerate). H_0 prepared from isovaleric acid (Sigma 
Chemical Company, St. Louis, MO) as described in Materials and Methods. 
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by federal graders. 
Experiment 2 
The second experiment (Exp. 2) consisted of two replicate trials. 
In the first trial, 30 mixed-breed ram lambs, weighing 21 kg, were 
randomly allocated to one of four dietary treatment groups: 1) leucine 
(n-7), 2) KIC (n~8), 3) IVA (n-8) or 4) limestone (control; n-8). In 
the second trial, 30 mixed-breed ram lambs, weighing 24 kg, were 
randomly allotted to one of four dietary treatments 1) leucine (n-7), 2) 
KIC (n-8), 3) IVA (n-7) and 4) limestone (control; n-8). All animals 
were fed a corn-soybean meal basal diet (Table 3) supplemented with 5 g 
ammonium chloride daily. The lambs were caged individually in a light-
and temperature-controlled environment with free access to water. 
Dietary treatments consisted of leucine, KIC, IVA or limestone 
(control), which were supplemented to the basal diet twice daily as 
zein-coated pellets (Table 2). Lambs were fed their respective pellets 
at a rate of 1 g/d for the first 6 wk, 1.5 g/d for wk 6-10 and 2 g/d 
for wk 10 to time of slaughter. These doses translate to about 1 g 
pellets per kg diet and 2.5 mmol leucine, KIC or IVA per kg diet (molar 
equivalent of .05% leucine added to the diet). 
Lambs were weighed weekly and total feed consumption for each 2 wk 
period was recorded. Jugular blood samples were collected after 4 and 5 
wk of treatment into polypropylene tubes, allowed to coagulate and 
centrifuged. Serum was stored at -70° C. 
Upon reaching approximately 50 kg body weight, lambs were fasted 18 
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Table 3. Composition of basal diet for lambs in Exp. 2 (Trials 1 and 
2)  
Ingredient % of total mix (as fed basis) 
Corn grain 60 
Expeller soybean meal* 21 
Dehydrated alfalfa meal^  10 
Molasses, sugarcane 7.5 
Corn oil^  .38 
Limestone .50 
Salt .50 
Vitamin A premix^  .10 
Trace mineral premix® .02 
Calculated; 
Dry matter, % 88 
Crude protein, 17 
Metabolizable protein, g/kg® 124 
f Leucine, % 1.8 
Net energy-  ^
maintenance, Mcal/kg 1.9 
gain, Mcal/kg^  1.3 
fSoy-Plus, West Central Cooperative, Ralston, lA. 
20% crude protein. 
°Mazola, CPC International., Englewood Cliffs, NJ. 
Ca, 13-15%; Zn 12%; Mn 8.0%; Fe 10%; Cu 1.5%; I .2%; Co .1%; 
Calcium Carbonate division of J. M. Ruber Corporation, Quincy, IL. 
®5,200,000 lU Vitamin A/kg, Hoffmann-LaRoche, Nutley, NJ. 
Calculated from National Research Council values (1982). 
C^alculated from Burroughs et al. (1974). 
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hr and killed by electrical shock and exsanguinatlon. Wool growth was 
measured by clipping a known marked area on both sides of the lamb both 
at the start and at the conclusion of the trials. Carcass, perirenal 
fat, left and right gastrocnemius muscles, left and right psoas major 
muscles and left and right longissimus dorsi muscles (posterior to 10th 
rib) were separated and weighed. Carcasses were severed between the 
10th and 11th ribs; backfat thickness and longissimus area were 
measured. The right tibia and right femur were separated and cleaned, 
and length and weight were recorded. 
Treatment Supplement Preparation 
Treatment pellets, resistant to ruminai degradation, were made by 
thoroughly mixing zein and 88% ethane1 and adding limestone, bentonite 
and either Ca (KIG)2, Ca (IVA)^ , leucine or more limestone in the ratios 
presented in Table 2. This mixture was extruded through a 3-mm die 
directly into a vat of liquid nitrogen for freeze-fracturing. The 
frozen, shattered pellets were allowed to dry slowly at room 
temperature. After drying, the pellets were shaken under forced air and 
sprayed with a solution of 20% zein in 88% ethanol (100 ml/kg pellets). 
Average pellet size was 2x8 mm, and density was 1.1 to 1.2 g/ml. 
Ruminai incubation of the pellets in a dacron bag indicated that ruminai 
bypass of the zein-protected compounds was approximately 60% (VandeHaar 
et al., 1987). Ca (IVA)^  was made by combining slightly excess calcium 
hydroxide on a molar basis with IVA. The salt produced was calculated 
to be 73% Ca (IVA)^ . 
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Wool Analysis 
After an initial weighing, wool was rinsed with water to remove 
dirt and debris, dried at 60° C and rewelghed. The wool was then rinsed 
with chloroform to extract fat, dried at 60° C and rewelghed to obtain a 
fat-free wool weight. 
Plasma Metabolite Analysis 
Plasma leucine and KXC were analyzed by adding 20 nmol 
«(-ketocaproate (KG) and 150 nmol norleuclne (NL) as internal standard to 
1 ml plasma. After deproteinlzlng with .75 N perchlorate and separation 
of amino and keto acids via cation exchange column (Nissen et al., 
1982), the extracts were dried under nitrogen gas and derivatized with 
100 ul pyridine plus 100 ul N-methyl-N (t-butyl-dimethyIsllyl) 
trifluoroacetamide containing 1% t-butyldimethyl-chlorosilane (Regis 
Chemical Company, Morton Grove, IL). KIC and KG were monitored at 301 
AMU and leucine and NL were monitored at 302 AMU by using a gas 
chromatography-mass spectrometry system (Hewlett-Packard 5970a). 
Concentrations were calculated by comparing the KIC to KG peak height 
ratios and leucine to NL peak height ratios with that of the standards. 
An automated system (Rotochem IIA, Travenol Laboratories, 
Deerfleld, IL) was used with enzymatic and colorlmetrlc kits for 
determination of plasma glucose (Glucose (HK) Reagent, Gilford Systems, 
Oberlin, OH), blood urea nitrogen (BUN; BUN Reagent, Gilford Systems, 
Oberlin, OH), albumin (SpecTru BGG Albumin Reagent, Pierce Chemical 
Company, Rockford, IL), and phosphorus (Worthington Inorganic Phosphorus 
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Reagent Set, Cooper Biomedical, Inc., Malvern, PA). As plasma from Exp. 
1 was collected into tubes with EDTA, calcium values from these trials 
were not reported. 
Plasma Hormone Analysis 
Plasma was analyzed for Cortisol concentration by radioimmunoassay 
(Amerlex Cortisol Kit, Amersham Corporation, Arlington Heights, IL). 
Plasma insulin concentration was determined by radioimmunoassay by using 
bovine insulin antibody (Trenkle, 1972). The concentration of insulin-
like growth factor (IGF-I) in plasma was measured by Dr. Ted Elasasser 
(USDA-ARS, Beltsville, MD) by radioimmunoassay by using human IGF-I 
antibody (Underwood et al., 1982). 
Statistical Analysis 
In Exp. 1, statistics were performed by using the general linear 
model procedure of SAS (SAS, 1985), examining the dose-resposive effect 
of KIC on the different variables with pen as the experimental unit. 
The linear and quadratic effects of KIC were tested using an F-test. In 
Exp. 2, data from trials 1 and 2 were analyzed together and statistics 
were performed on the various variables with analysis of variance of a 
replicated model that included diet, experiment and diet x experiment by 
using the general linear model procedure of SAS (SAS, 1985). F-test 
with 3 and 47 degrees of freedom was used to test for significance of 
diet effects, whereas t-test was used to ascertain the probability of 
differences between treatments. 
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RESULTS 
The effect of orally administered KIC protected from ruminai 
degradation on cattle performance is reported in Table 4. During the 
first 30 days of the trial, daily gain tended to be increased by 29%, 
17% and 18% for the .02%, .07% and .20% KIC treatments, respectively 
(probability of a greater F for quadratic-dose response - .20). Daily 
feed intake was not altered. Feed conversion was improved 13%, 9% and 
10% for the .02%, .07% and .20% KIC treatments, respectively 
(probability of a greater F for quadratic-dose response - .12). 
Over the entire 161-d trial, daily gain was increased by KIC in a 
quadratic dose-responsive manner (p<.03). Daily gain was increased by 
14% and 7% for the .02% and .07% KIC treatments, respectively. Daily 
feed intake was not significantly altered. Feed conversion tended to be 
improved 8% and 6% for the .02% and .07% KIC treatments, respectively 
(probability for a greater F for quadratic-dose response - .26). 
The effect of feeding rumen-protected leucine and its metabolites 
to lambs on growth, feed intake, feed conversion and wool growth is 
presented in Table 5. Whereas daily gain was increased 8% and feed 
conversion was improved 5% for lambs fed KIC, these were not statistically 
significant (p<.27 and p<.36, respectively). Daily feed intake and 
fat-free wool gain were not significantly altered. Leucine and IVA 
treatment did not significantly alter daily gain, feed intake, feed 
conversion or wool gain. 
In Exp. 1, one steer in the control group died and one steer was 
treated for sickness, whereas no animals from the KIC-treated groups 
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Table 4. The effect of feeding rumen-protected o^ ketolsocaproate (KIC) 
on steer growth, intake and feed conversion (Exp. 1) 
Parameter 0 
% Dietary KIC-
.02 .07 .20 SEM® p>F^  
Starting wt., kg 263 263 263 264 8 
Daily gain, kg 
0-30 days 1.33 1.72 1.55 1.57 .13 .20 
0-74 days 1.37 1.56 1.48 1.53 .06 .37 
0-128 days 1.27 1.44 1.35 .03 .04 
0-161 days 1.21 1.38 1.30 .03 .03 
Daily intake, kg DM/day 
0-30 days 6.5 6.9 6.7 6.8 .3 .54 
0-72 days 7.8 8.3 8.0 8.0 .4 .56 
0-128 days 8.7 9.1 8.7 .3 .45 
0-161 days 9.1 9.5 9.1 .4 .40 
Feed/gain 
0-30 days 5.0 4.0 4.3 4.4 .3 .12 
0-72 days 5.7 5.3 5.4 5.2 .2 .07 
0-128 days 6.9 6.3 6.5 .3 .30 
0-161 days 7.5 6.9 7.0 .2 .26 
S^EM is the pooled standard error of the mean. 
P^robability of a greater F for quadratic-dose response of KIC. 
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Table 5. The effect of rumen-protected leucine (Leu), dfketoisocaproate 
(KIC), or isovalerate (IVA) for approximately 100 days on lamb 
growth, intake, feed conversion and wool growth 
Control Leu KIC IVA S EM® P>F^  P>F'^  
n 13 12 16 12 
Start weight, kg 23.2 22.6 23.0 22.6 .8 .96 .97 
Days to slaughter 101 99 93 98 5 .67 .28 
Daily gain, g 282 294 306 295 14 .70 .27 
Daily intake, g 1330 1370 1370 1330 40 .89 .53 
Feed/gain 4.81 4.78 4.55 4.82 .19 .75 .36 
Fat-freegWool gain, 
mg/(cm -d) 2.09 1.98 2.09 1.95 .12 .78 .95 
S^EM is pooled standard error of the mean. 
P^robability of > F for overall model. 
^^ Probability of > F for contrast between control and KIC means. 
86 
died or were treated. There was one condemned liver in the control 
group and one in the 0.07% KIC treatment group. In Exp. 2 Trial 1, two 
control lambs, one lamb fed leucine and one fed IVA developed urinary 
calculi or other complications and were removed from the study, whereas, 
in Exp, 2 Trial 2, one control lamb, one lamb fed leucine and one fed 
IVA were removed from the study because of urinary calculi and other 
complications. 
The effect of KIC on steer carcass composition is listed in 
Table 6. Carcass weight was increased by KIC in quadratic dose-
responsive manner (p<.06). Dressing percentage, longissimus area, 
backfat thickness, perirenal, pericardial and pelvic fat and yield grade 
were not affected by the addition of KIC to the diet. However, the 
number of cattle grading choice or prime was significantly increased in 
a linear dose-dependent manner by the addition of KIC (p<.02). Whereas 
approximately 70% of the control cattle graded choice or prime, 90% on 
the .02% and 100% on the .07% KIC treatment graded choice or prime. 
The effect of feeding leucine and its metabolites on lamb organ 
weight is presented in Table 7. The weight of carcass, liver, spleen, 
heart, kidneys, testis or adrenal glands, expressed as a percentage of 
body weight, were not altered as result of treatment. Percentage lungs 
were increased by KIC treatment (p<,01). 
Carcass composition of lambs fed rumen-protected leucine and its 
metabolites is presented in Table 8. Fat thickness over the 11th rib 
was decreased by 17% when KIC treatment was compared with controls 
(p<,04). Perirenal fat and longissimus area were not significantly 
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Table 6. The effect of feeding rumen-protected O^ ketoisocaproate (KIC) 
for 161 days on steer carcass composition 
DlGùâiry KIC--"-
Parameter 0 .02 .07 SEM® P>F^  
Final weight, kg 462 485 470 12 .03 
Carcass weight, kg 275 290 282 9 .06 
Carcass, %° 60.0 59.8 59.7 .2 .54 
2 Longissimus area, cm 72.2 72.9 72.2 2.3 .94 
Backfat thickness, mm 8.3 8.6 7.9 .6 .51 
Internal fat, 2.1 2.1 2.0 .1 .67 
Yield grade 1.8 2.0 1.9 .1 .22 
Quality grade: 
% Prime and choice® 69.7 88.9 100.0 6.1 .02 
% Good^  29.4 11.1 0.0 6.1 .02 
Marbling score® Small 50 Small 90 Modest 10 20 .54 
5sEM is the pooled standard error of the mean. 
Probability of a greater F for linear-dose response of KIC, 
except carcass weight and yield grade, which were for quadratic-dose 
response. 
P^ercentage of final body weight. 
Perirenal, pericardial and pelvic fat as a percentage of final 
body weight. 
P^ercentage of steers grading prime and choice. 
Percentage of steers grading good. 
M^arbling score graded in units of Slight 10, 20, ... 90; Small 10, 
20, ... 90; Modest 10, 20, ... 90; Moderate 10, 20, ... 90. SEM in 
units of 10. 
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Table 7. The effect of feeding rumen-protected leucine (Leu), 
d^ ketoisocaproate (KIC) or isovalerate (IVA) for 
approximately 100 days on lamb organ weight 
Control Leu KIC IVA SEN* P>F^  P>F'^  
Final weight. kg 50.7 50.9 51.0 50.9 .6 .98 .68 
Carcass, 52.1 52,1 53.1 52.8 .7 .65 .29 
Liver, 1.68 1.82 1.79 1.73 .05 .37 .22 
Spleen, .213 .208 .228 .185 .011 .08 .31 
Heart, .41 .42 .42 .42 .01 .75 .32 
Lungs, .90 1.01 1.10 .96 .05 .07 .01 
Kidney, %'^  .28 .31 .30 .30 .01 .33 .22 
Testis, .47 .51 .44 .46 .03 .37 .46 
Adrenal , 
glands, % X 1000 4.99 4.96 5.18 5.01 .08 .94 .63 
S^EM is pooled standard error of the mean. 
P^robability of > F for overall model. 
P^robability of > F for contrast between control and KIC means. 
"^ Percentage of final body weight. 
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Table 8. The effect of feeding rumen-protected leucine (Leu), 
eC^ ketoisocaproate (KIC) or isovalerate (IVA) for 
approximately 100 days on lamb carcass composition 
Control Leu KIC IVA SEM^  P>F^  P>F° 
Backfat, mm 7.0 6.8 5.8 6.4 .5 .19 .04 
Perirenal fat, 1.53 1.28 1.26 1.44 .16 .57 .22 
Longissimus g 
area, cm 2.69 2.63 2.61 2.56 .12 .83 .51 
Psoas major, .284 .282 .314 .300 .012 .16 .07 
Longissimus, .788 .807 .849 .793 .022 .18 .05 
Gastrocnemius, .111 .117 .124 .107 .004 .08 .07 
Tibia, .257 .271 .269 .250 .006® .03 .09 
Humerus, %** .145 .160 .164 .147 .003^  .01 .00( 
Tibia, cm 20.7 21.0 20.8 20.7 .2 .69 .51 
Humerus, cm 13.3 13.7 13.5 13.4 .2 .48 .90 
Tibia, g/cm 6.30 6.11 6.60 6.11 .13 .05 .09 
Humerus, g/cm 5.21 5.64 5.79 5.28 .14 .05 .04 
S^EM is pooled standard error of the mean. 
P^robability of > F for overall model. 
'^ Probability of > F for contrast between control and KIC means. 
*^ Percentage of final body weight. 
P^robability of > F for contrast between control and leucine means 
-  .08 .  
P^robability of > F for contrast between control and leucine means 
—  . 0 6 .  
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affected by treatment. However, KIG increased psoas, longissimus and 
gastrocnemius muscle weights by 11% (p<.07), 8% (p<.05) and 12% (p<.07), 
whereas leucine and IVA did not significantly affect these parameters, 
KIC and leucine both increased tibia weight as a percentage of body 
weight 5% (p<.09 and p<.08, respectively) and increased humerus weight 
13% (p<.006) and 10% (p<.06), respectively. IVA did not alter tibia or 
humerus weight. The length of these bones were not altered due to 
treatment. The weight per length of the tibia was increased 5% (p<.09) 
and 4% (p<.17) for KIC and leucine treatments, respectively. The weight 
per length of humerus was increased 11% (p<.04) and 8% (p<.19) for the 
KIC and leucine treatments, respectively. IVA did not affect the weight 
per length in either bone. 
The effect of KIC on steer plasma parameters is reported in Table 
9. Plasma glucose concentration was decreased in a linear dose-
responsive manner (p<.04). KIC fed at .02% and ,07% of the diet 
decreased glucose 16% and 19%, respectively. Plasma albumin, BUN and 
phosphous concentrations were not affected by treatment. 
Cattle Cortisol concentrations were decreased quadratically (p<.02) 
by 19% and 14% for the .02% and .07% KIC treatments, respectively. 
Plasma IGF-I and insulin concentrations were not altered. However, 
glucagon concentrations were decreased and consequently insulin/glucagon 
were increased in a linear dose-responsive manner (p<.09 and p<.06, 
respectively). 
The effect of leucine and its metabolites fed to lambs on plasma 
parameters is presented in Table 10. Although leucine and IVA did not 
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Table 9. The effect of feeding rumen-protected dfketoisocaproate (KIC) 
for 72 days on steer plasma parameters 
- - - • % Dietary KIC 
Parameter 0 .02 .07 SEM® P>F^  
KIC, uM 20.4 22.4 19.8 2.7 .76 
Leucine, uM 256 233 240 19 .72 
Glucose, mg/dl 116 97 94 6 .04 
BUN, mg/dl 13.0 13.7 14.0 .6 .22 
Albumin, mg/dl 3.99 4.05 3.93 .1 .71 
Phosphorus, mg/dl 10.1 10.0 10.1 .5 .99 
Cortisol, ng/dl 3.47 2.80 2.99 .11 .02 
IGF-I, ng/ml 120 113 118 12 .96 
Insulin, ng/ml 1.30 1.14 1.20 .21 .83 
Glucagon, pg/ml 1428 818 697 219 .09 
Insulin/glucagon .99 1.41 1.74 .21 .06 
^SEM is the pooled standard error of the mean. 
^Probability of a greater F for linear-dose response of KIC with 
the exception of Cortisol, which is for a quadratic-dose response. 
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Table 10. The effect of feeding rumen-protected leucine (Leu), 
o(-ketoisocaproate (KIC) or isovalerate (IVA) for 
approximately 28 days on lamb serum parameters 
Control Leu KIC IVA SEM^  P>F^  P>F° 
KIC, uM 22.7 21.2 19.5 20.9 1.8 .63 .20 
Leucine, uM 217 228 218 248 17 .58 .99 
Glucose, mg/dl 89 85 90 88 2 .55 .81 
Albumin, mg/dl 4.05 3.82 4.02 4.02 .08 .20® .87 
BUN, mg/dl 21.5 22.1 23.8 23.4 1.2 .40 .12 
Calcium, mg/dl 10.7 10.3 10.7 10.7 .1 .23^  .98 
Phosphorus, mg/dl 9.3 9.0 10.2 9.8 .3 .04 .04 
Cortisol, ug/dl 2.31 3.17 3.65 2.59 .46 .14 .03 
IGF-I, ng/ml^  203 212 220 201 15 .82 .57 
Insulin, ng/ml 1.47 1.79 1.63 1.65 .35 .99 .76 
Glucagon, pg/ml^  326 321 295 295 16 .40 .19 
Insulin/glucagon^  2.68 3.33 3.43 2.56 .42 .19 .22 
S^EM is pooled standard error of the mean. 
'^ Probability of > F for overall model. 
P^robability of > F for contrast between control and KIC means. 
'Values from trial 1 only. 
P^robability of > F for contrast between control and leucine means 
— . 06 .  
£ Probability of > F for contrast between control and leucine means 
- .11. 
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alter plasma leucine and KIG concentrations, KIG treatment did result in 
a lowered level of plasma KIG (p<.06). Glucose, albumin and BUN levels 
were not altered due to leucine, KIG or IVA, with the exception that 
leucine decreased plasma albumin (p<.06). Whereas KIG and IVA did not 
alter plasma calcium, there was a trend for leucine to decrease calcium 
(p<.ll). Phosphorus levels were increased by KIG 10% (p<.04) but were 
not altered by leucine or IVA treatment. 
In Exp. 2, plasma Cortisol was increased by KIG (p<.03), whereas 
leucine and IVA had no affect. IGF-I, insulin, glucagon and 
insulin/glucagon were not altered by leucine or its metabolites. 
Discussion 
Oral administration of ruminally-protected KIG altered steer and 
lamb growth rates as effectively as larger doses delivered 
intraperitoneally or orally in an unprotected form. Gattle responded to 
KIG supplementation early in the experiment, with the greatest response 
being 29% at 30 days with .02% KIG. Although response to KIG was greater 
early in the trial, a significant response was maintained over the 
duration of the trial. The 0.02% KIG treatment continued to provide the 
greatest response (14% increase) throughout the trial. 
In Exp. 2, the lambs also had greater response to KIG early in the 
trials (23% at 28 days, p<.15; data not shown). Over the duration of 
the trial, there was a trend for KIG (5 g/d) to increase gain 8% and 
feed conversion 5%. These data are consistent with results from 
previous trials (Flakoll and Nissen, 1986; Flakoll et al., 1986) in 
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which, when KIC was administered intraperitoneally (3 g/d), gain was 
increased 11% and, when KIC was administered unprotected orally (15 g/d), 
gain was increased 10%. 
Cattle subcutaneous and internal fat depots were not altered by 
KIC, whereas these fat depots in lambs were decreased 17 and 18%, 
respectively. This fat decrease in lambs is similar to previous trials 
where intraperitoneal KIC decreased subcutaneous fat 28% and perirenal 
fat 13% (Flakoll and Nissen, 1986,) and oral KIC decreased subcutaneous 
fat 18% and intraperitoneal fat 14% (Flakoll et al., 1986). 
The reason for the differences between the cattle and lamb 
experiments may lie in the differences in how the experiments were 
terminated. Lambs were killed at the same final weight, whereas the 
cattle were killed at the same time, resulting in different final 
weights between treatments. It could be postulated that, if the control 
cattle were fed to an equivalent final weight, they would have had more 
marbling and a greater percentage would have graded choice or prime. 
However, it is likely that feeding the control animals to an increased 
weight would have resulted in increased subcutaneous and Internal fat 
depots and worsened yield grades and feed converisons. 
In addition to decreasing internal and external fat depots in 
lambs, KIC increased muscle weight. The most likely mechanism whereby 
this would occur would be through its proposed effects on decreasing 
protein degradation (Chua et al., 1979; Poso et al., 1982; Tischler et 
al., 1982) or increasing protein synthesis (Kirsch et al,, 1976). 
Additionally, KIC increased insulin to glucagon ratios in both 
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experiments, which would tend to decrease protein turnover and favor 
increased protein deposition. KIC also decreased the catabolic hormone 
Cortisol in the cattle experiment, which should favor increased gain. 
In lambs, however, KIC increased Cortisol concentrations. The reason for 
these opposing effects is unclear. 
KIC and leucine increased tibia and humerus weights as percentage 
of the body weight. This is similar to a previous study where 
intraperitoneal KIC increased percent bone and bone density (Flakoll and 
Nissen, 1986; Flakoll et al., 1986). Both leucine and KIC reduced 
plasma calcium to phosphorus ratios. Whereas leucine accomplished this 
by reducing plasma calcium, KIC increased plasma phosphorus. 
Previous studies with KIC have demonstrated decreased plasma phosphorus 
and increased calcium to phosphorus (Walser, 1975; Heidland et al., 
1978; Frohling et al., 1980; Kampf et al., 1980; Attman et al., 1984). 
The alteration of phosphorus metabolism may involve the reduction of 
parathyroid hormone concentrations, which have been reported to decrease 
during ketoacid therapy (DiLandro et al., 1982; Schmicker et al., 1982; 
Lindenau et al., 1982; Barsotti et al., 1982). IGF-I is also known to 
alter bone metabolism. However, plasma IGF-I concentrations were not 
altered in these studies. 
It should be noted that animals in these experiments were on a high 
plane of nutrition. This was done to ensure that animals would be 
supplied with a slight excess of nutrients to allow for increased 
growth. It could be argued, however, that KIC may be more effective 
when nutrients are limiting, as it has been shown that KIC improves 
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nitrogen balance in fasting humans (Sapir and Walser, 1977). Further 
research is required to define nutrient interaction with KIC treatment. 
Feeding leucine and IVA did not significantly affect growth or fat 
and muscle deposition. This may possibly be explained by the 
physiological differences In the metabolism between the different 
leucine metabolites. Whereas leucine, KIC and IVA share the same 
metabolic pathway, their site of metabolism is distinctly different. 
The liver is limiting in branched chain amino acid transaminase, so very 
little dietary leucine is catabolized until it reaches extrahepatic 
tissues (Ichihara and Koyama, 1966; Krebs and Lund, 1977). Conversely, 
the liver contains abundant quantities of branched chain ketoacid 
dehydrogenase (Shlnnlck and Harper, 1976), which is the enzyme 
responsible for the first irreversible step of KIC oxidation in which 
KIC is converted to Isovaleryl-CoA. Therefore, an oral dose of leucine 
would be expected to undergo very little catabollsm by the splanchnic 
tissues. It has been estimated that 70 to 95% of an oral branched chain 
amino acid load escapes the gut and liver tissues (Elwyn et al., 1968; 
Bloomgarden et al., 1981). In contrast, KIC would be expected to be 
extensively catabolized while passing through the splanchnic area. In 
dogs, it has been demonstrated that 85% of an oral dose of KIC is 
metabolized by the splanchnic tissues (Abumrad et al., 1982; Sassier and 
Pletrek, 1983). 
IVA would be expected to be metabolized in the same sites as KIC. 
However, IVA cannot be converted back to KIC. Therefore, if IVA effects 
mimicked KIC, it could be assumed that KIC acted through IVA. However, 
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this was not the case in the present experiments, because IVA did not 
produce similar effects to KIC. 
It was noted that the plasma concentrations of glucose, Cortisol, 
and glucagon in the cattle experiment were above that which would 
normally be expected, indicating that the animals may have been under 
stress. This may have been the case as each animal was placed in a 
mechanical squeeze-shoot, immobilized with a halter and blood sampled 
via venipuncture. Additionally, the weather during this period was wet 
and cold (-5° C). The reported lowering of stress indicators 
Cortisol and glucagon may provide insight into another possible 
mechanism for KIC. KIC could suppress the catabolic action of stress 
hormones, resulting in increased gain. This may explain the observation 
of increased response to KIC early in the experiments when stress is 
thought to be greater. Additional support for this mechanism is found 
in studies with lambs and cattle where lymphocyte blastogenesis and 
antibody production are increased with KIC treatment (Nissen et al. 
1986; Flakoll et al., 1987; Kuhlman et al., 1987). 
In conclusion, while the optimal dose may differ for various 
metabolic effects, supplemental KIC protected from ruminai degradation 
has the potential to improve growth and alter energy and protein 
partitioning in cattle, whereas leucine and IVA did not produce similar 
responses. 
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SECTION III. MUSCLE GROWTH AND WHOLE-BODY LEUCINE, PHENYLALANINE AND 
3-METHYLHISTIDINE METABOLISM OF GROWING LAMBS FED LEUCINE, 
0(-KETOISOCAPROATE AND ISOVALERATE PROTECTED FROM RUMINAL 
DEGRADATION 
Abstract 
Leucine (Leu; n-6) and its metabolites, O^ ketoisocaproate (KIC; 
n-8), isovalerate (IVA; n-6) and limestone (control; n-6) were fed in a 
ruminally-protected form at 0.05% of the diet to growing ram lambs to 
determine effects on whole-body Leu, KIC, phenylalanine (Phe), tyrosine 
(Tyr) and 3-methylhistidine (3MH) metabolism by using primed-dose 
constants infusion of [6,6,6-^ H2] Leu, [1-^ C^] KIC, [1-^ C^] Phe and 
2 3-methyl- H^ -histidine. Subcutaneous fat thickness was decreased 24% 
(p<.08) and 23% (p<.09) by KIC and IVA, respectively. Perirenal fat 
depots were decreased 44% (p<.005) and 27% (p<.07) by KIC and Leu, 
respectively. KIC increased psoas major, longissimus and gastrocnemius 
muscle weight by 13% (p<.06), 8% (p<.15) and 9% (p<.13), respectively. 
Leu used for protein synthesis (avg 4.42 umol/(min*kg)), Leu from 
proteolysis and absorption (avg 4.66 umol/(min*kg)), KIC transamination 
to Leu (avg .62 umol/(min*kg)), KIC oxidation (avg .22 umol/(min*kg)), 
Phe flux (avg 1.29 umol/(min*kg)), Tyr derived from Phe (avg 51.8%) and 
3MH flux (avg 12.0 nmol/(min*kg)) were not significantly altered by 
dietary treatment. Leu transamination to KIC (avg .83 uraol/(min*kg)) 
was increased for the Leu-treated lambs (p<.06). In conclusion, 
although KIC increased muscle mass, it does not seem to occur through 
protein-sparing. 
(Keywords: Lambs, Leucine, 6^ -Ketoisoc.iproate, Muscle growth. 
Phenylalanine, 3-Methylhistidine.) 
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INTRODUCTION 
Initial experiments have shown that o^ ketolsocaproate (KIC) can 
improve lamb and cattle growth. When lambs were injected 
intraperitoneally with 3 g KIC daily, growth was improved 11% (Flakoll 
et al., 1988a), whereas lambs fed approximately 15 g KIC daily had 
increased gains of 10% (Flakoll et al., 1988a), KIC protected from 
ruminai degradation increased growth 8% when fed to lambs at 
approximately .75 g daily (Flakoll et al., 1988b). Steers fed 
approximately 1.3 g KIC protected from ruminai degradation had gain 
increased by 14% (Flakoll et al., 1988b). In addition to effects on 
growth, KIC was demonstrated to increase milk and milk fat production in 
lactating cattle 10 and 8%, respectively (VandeHaar et al., 1988). 
In each of the lamb trials, internal and external fat depots were 
decreased (Flakoll et al., 1988a,b), whereas psoas, gastrocnemius and 
longlsslmus muscles dissected from lambs fed KIC protected from ruminai 
degradation were approximately 10% larger than that of the controls 
(Flakoll et al., 1988b). These data suggest that some aspect of muscle 
protein metabolism is altered by KIC. These findings in ruminants are 
supported by data in human studies in which nitrogen balance was 
improved by KIC treatment during fasting (Mitch et al., 1981), 
postsurgical trauma (Sapir et al., 1983) and renal failure (Ell et al., 
1978). 
Metabolites of KIC, leucine and Isovalerate (IVA), have also been 
proposed to be important in regulation of protein metabolism. Leucine 
has been found to Increase protein synthesis (Morgan et al., 1971; Buse 
105 
and Reld, 1975), whereas IVA has been reported to decrease proteolysis 
(Chua et al., 1979). 
Therefore, the present experiment was designed to determine if 
leucine metabolites affect whole-body protein metabolism by measuring 
the flux of leucine and an amino acid unrelated to leucine, 
phenylalanine. Additionally, possible effects of leucine metabolites on 
muscle proteolysis was determined by measuring the flux of 
3-methylhistidine. 
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MATERIALS AND METHODS 
Animals and Diets 
Thirty mixed-breed ram lambs, weighing 21 kg, were randomly 
allocated to one of four dietary treatment groups: 1) leucine, 2) KIC, 
3) IVA or 4) limestone (control). All animals were fed a corn-soybean 
meal basal diet (Table 1) supplemented with 5 g ammonium chloride daily. 
The lambs were caged individually in a light- and temperature-controlled 
environment with free access to water. 
Dietary treatments consisted of leucine (n-7), KIC (n-8), IVA (n-7) 
or limestone (control; n-8), which were supplemented to the basal diet 
twice daily as zein-coated pellets (Table 2). Lambs were fed their 
respective pellets at a rate of 1 g/d for the first 6 wk, 1.5 g/d for wk 
6-10 and 2 g/d for wk 10 to time of slaughter. These doses translate 
to about 1 g pellets per kg diet, which is equivalent to 2.5 mmol 
leucine, KIC and IVA per kg diet or about .05% leucine added to the 
diet. 
Pellets were made by thoroughly mixing zein and 88% ethanol 
and adding limestone, bentonite and either Ca(KIC)2, Ca(IVA)2, leucine 
or more limestone. This mixture was extruded through a 3-mm die 
directly into a vat of liquid nitrogen for freeze-fracturing. The 
frozen, shattered pellets were allowed to dry slowly at room 
temperature. After drying, the pellets were shaken under forced air and 
sprayed with a solution of 20% zein in 88% ethanol (100 ml/kg pellets). 
Average pellet size was 2 x 8 mm and density was 1.1 -1.2 g/ml. Ruminai 
inoculation of KIC in Dacron bags indicated that ruminai bypass of the 
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Table 1. Composition of basal diet for lambs 
Ingredient % of total mix (as fed basis) 
Corn grain 
Expsller soybean meal* 
Dehydrated alfalfa meal^  
Molasses, sugarcane 
Corn oll° 
Limestone 
Salt 
Vitamin A premix^  
Trace mineral premlx® 
Calculated: 
Dry matter, % 
f Crude protein, % 
Metabolizable protein, 
f Leucine, % 
Net energy- maintenance, Mcal/kg^  
f Net energy- gain, Mcal/kg 
60 
21 
10 
7.5 
.38 
.50 
.50 
.10 
.02 
88 
17 
124 
1 . 8  
1.9 
1.3 
fSoy-Plus, West Central Cooperative, Ralston, lA. 
20% crude protein. 
M^azola, CPC International., Englewood Cliffs, NJ. 
Ca, 13-15%; Zn 12%; Mn 8.0%; Fe 10%; Cu 1.5%; I .2%; Co .1%; 
Calcium Carbonate division of J. M. Huber Corporation, Quincy, IL. 
|5,200,000 lU Vitamin A/kg, Hoffmann-LaRoche, Nutley, NJ. 
Calculated from National Research values (1982). 
C^alculated from Burroughs et al. (1974). 
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Table 2. Composition of treatment supplements* 
Ingredient Leucine KIC IVA Control 
g/kg 
Zein^  450 450 450 450 
Ethanol 278 278 278 278 
Water 37 37 37 37 
Limestone,° 16 10 8 45 
Sodium Bentonite,^  5 5 5 10 
Leucine® 340 
f 0(-Ketoisocaproate 400 
Isovalerate® 420 
*Dried treatment pellets contained approximately 2.5 mol leucine, 
KIC, or IVA, and 64, 91, 97, or 180 g calcium per kg leucine, KIC, IVA, 
or control pellets, respectively. 
F^reeman Industries, Tuckahoe, NY. 
3^25 mesh; Iowa Limestone Company, Des Moines, lA. 
2^00 mesh; American Colloid Company, West Des Moines, lA. 
S^igma Chemical Company, St. Louis, MO. 
C^a (0(fketoisocaproate)2 HgO; SOBAC, Rue Saint-Honore, 75001, 
Paris, France. 
®Ca (isovalerate)2 H-O prepared from isovaleric acid (Sigma 
Chemical Company, St. Louis, MO) as described in Materials and Methods. 
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compounds was approximately 60% (VandeHaar et al., 1987). Ca(lVA)2 was 
made by combining calcium hydroxide with IVA. 
Lambs were weighed weekly and total feed consumption for each two 
week period was recorded. During the study, two control lambs, one lamb 
fed leucine and one fed IVA developed urinary calculi or other 
complications and were removed from the experiment. 
When animals weighed approximately 50 kg, they were fasted 18 hr and 
electrically stunned and exsanguinated. Perirenal fat, left and right 
gastrocnemius muscles, left and right psoas major muscles, and left and 
right longlssimus dorsi muscles (posterior to tenth rib) were separated 
and weighed. Carcasses were severed between the tenth and eleventh 
ribs; backfat thickness and longlssimus area were measured. 
Isotope Infusion Study 
During wk 8, when lamb average body weight was 40 kg, 4 lambs daily 
were infused with stable isotopes to study the flux of leucine, KIC, 
phenylalanine and 3-methylhistidine. On the day before each study, 
lambs were removed from feed at 2000 hr and placed in metabolism stalls. 
At 0730 hr on the day of study, lambs were fed 50 g of feed with .75 g of 
their respective treatment pellets. Both the right and left jugular 
veins were catheterized, and at about 1000 hr a primed dose-continuous 
infusion of [6,6,6-^ Hg] leucine, [1-^ C^] KIC, [1-^ C^] phenylalanine and 
2 3-methyl- Hg-histidine was begun into the right jugular vein (Table 3). 
After a 120-min equilibration period, blood was sampled from the 
left jugular vein every 15 min from 120 min to 180 min. Blood was 
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Table 3. Infusion rate of isotopes 
Priming dose Steady state dose 
(mg)* (mg/min) 
[6,6,6-2%^ ] L-Leuclne^  14.1 0.364 
[1-^ C^] L-Phenylalanine*^  12.1 0.312 
[1-^ C^] 2-Ketolsocaproate° 
(sodium salt) 
14.1 0.364 
3-Methyl--L-histidine^  0.113 0.00291 
I^nfused over the first 10 min. 
M^SD Isotopes, St. Louis, MO. 
T^racer Technologies, Inc., Newton, MA. 
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collected into sodium EDTA-coated tubes and immediately put on ice until 
centrifugation; plasma was then stored at -70°C. 
Plasma Metabolite Analysis 
Concentrations of plasma leucine, KIC, phenylalanine and tyrosine 
were analyzed by adding 20 nmol -ketocaproate (KC) and 150 nmol 
norleucine (NL) as internal standard to 1 ml plasma. After 
deproteinizlng with 3 ml .75 N perchlorate, the amino and keto acids 
were separated via cation exchange column. The keto acids were 
collected into 35 ml of methylene chloride and back extracted with .5 ml 
of .05 N NaOH (Nissen et al., 1982). The amino acids were eluted from 
the column with 4 ml 25% NH^ OH. Keto and amino acid extracts were dried 
under nitrogen gas with 55° C heat and derivatized with 100 ul pyridine 
plus 100 ul N-methyl-N (t-butyl-dime thy1s ily1) trifluoroacetamide 
containing 1% t-butyldimethylchlorosilane (Regis Chemical Company, 
Morton Grove, IL). Using a gas chromatography-mass spectrometry system 
(Hewlett-Packard 5890/5970a), the keto acids, KIC and KC, were monitored 
at 301.2, 302.2, 303.2 and 304.2 AMU to determine m+1 (^ C^-KIC) and m+3 
2 ( Hg-KIC) enrichments of KIC, whereas the amino acids, leucine and NL, 
were monitored at 302.2, 303.2, 304.2 and 305.2 AMU to determine m+1 
13 2 ( C-leucine) and m+3 ( H^ -leucine) enrichments of leucine; 
phenylalanine and tyrosine were monitored at 302.2 and 303.2 to 
13 13 determine the m+1 ( C-phenylalanine and C-tyrosine) enrichments of 
phenylalanine and tyrosine. Concentrations of each in plasma were 
calculated by comparing the KIC-to-KC ratio and leucine-, phenylalanine-
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Table 4. 
Plasma 3-methylhistidlne was analyzed by adding 177 nmol of 1-
methylhlstldlne as an Internal standard to 2 ml of plasma. After 
deprotelnlzlng with 3 ml .75 N perchlorate, the supernatant was poured 
over a cation exchange column, and 3-methylhlstldlne was eluted from the 
column with 4 ml 25% NH^ OH and dried under nitrogen gas with 55° C heat. 
Additional heat (100° C for 15 mln) was provided to volatilize any 
remaining hydroscopic water. After cooling, 100 ul acetonltrile plus 
100 ul N-methyl-N (t-butyl-dime thy1s1ly1) trlfluoroacetamide (without 1% 
t-butyldimethyl-chlorosllane; Regis Chemical Company, Morton Grove, IL) 
was added and heated at 70° C for derlvatizatlon. After derivatlzation, 
a gas chromatograhy-mass spectrometry system (Hewlett-Packard 
5890/5970a) was used to detect 3-methylhistidlne at 238.1, 239.1, 240.1 
2 
and 241.1 AMU and determine m+3 (3-methyl- H^ -histldine) enrichment of 
3-methylhistidlne. Concentration of plasma 3-methylhlstldlne was 
determined by comparing the peak height ratios of 3-methylhlstldine to 
1-methylhistidine in standards versus plasma. Column temperatures and 
retention times are included in Table 4. Observed spectra of 3-
methylhlstidine are Illustrated in Figure 1. 
13 2 13 2 Enrichments of C-KIC, H^ -KIC, C-leucine and H^ -leucine were 
used to determine the whole-body flux of leucine and KIC, and estimate 
leucine to protein synthesis, leucine entry rate (from proteolysis and 
absorption), leucine and KIC Interconversion and KIC oxidation according 
to the equations of Nissen and Raymond (1981). Whole-body phenylalanine 
flux was estimated by the equation: phenylalanine flux - infusion rate 
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Table 4. Parameters for gas chromatography-mas s spectroscopy analysis 
of leucine (Leu), phenylalanine (Phe), tyrosine (Tyr), 
norleucine (NL), O^ ketoisocaproate (KIC), ^ ketocaproate 
(KG), 3-methylhistidine (3MH) and 1-methylhistidine (IMH)* 
Parameter Leu, Phe, Tyr, NL^  KIC, KC^  3MH, 1MH° 
Temperatures, C 
Inj ector 285 285 285 
Detector 285 285 285 
Oven-initial 100, . 1  5 min 100, 5 min 50, .5 min 
-ramp 1 40/min to 220 
Hold 2 min 
40/min to 220 
Hold 2 min 
40/min to 220 
Hold 5 min 
-ramp 2 60/min to 300 
Hold 1.2 min 
60/min to 300 
Hold 1.2 min 
40/min to 300 
Hold 1.3 min 
Retention times, min 
Leu 3.8 
NL 4.0 
Phe 5.3 
Tyr 
KIC 
7.0 
3,9 
KC 4.1 
3MH 7.8 
IMH 8.5 
Ions monitored, AMU 302.2, 303.2 301.2, 302.2 238.1, 239.1 
304.2, 305.2 303.2, 304.2 240.1, 241.1 
H^ewlett-Packard 5890 gas chromatograph and 5790a mass selective 
detector using splitless injection with purge off for .4 min and a 25 m 
long X .22 mm i.d. x .11 um film thickness, crosslinked silicon gum 
phase capillary column (HP-1, Hewlett-Packard, Avondale, PN). 
F^ormed di-derivative with N-methyl-N (t-butyl-dimethylsilyl) 
trifluoroacetamide containing 1% t-butyldimethylchlorosilane (Regis 
Chemical Company, Morton, IL). 
F^ormed di-derivative with N-methyl-N (t-butyl-dimethylsilyl) 
trifluoroacetamide without 1% t-butyldimethylchlorosilane (Regis 
Chemical Company, Morton, IL). 
114 
2 . 5 C 5  
2 . 0 E 5 -
0) 
u 
c 
nt 
•a 
c 
3 
Œ 
1 . 5 E 5 -
1 . 0 E 5 -
5 . 0 E 4 -
S c a n  7 2  ( 7 . 0 2 3  m i n )  o f  D f l T R î 3 M H S C f l N . D  
3  
2 3 8  
/  
1 8 0  
\  
i j  '• III'. U iMijj 
3 0 2  
3 4 0  
/  
100 200 
M a s s / C h a r g e  
3 0 0  
Figure 1. Spectral scan of 3-methylhistldine on a Hewlett-Packard 5790a 
mass selective detector 
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flux was estimated by the equation: phenylalanine flux - infusion rate 
13 13 
of C-phenylalanine / C-phenylalanine enrichment. The percentage of 
whole-body tyrosine from phenylalanine was calculated by the equation: 
13 % tyrosine from phenylalanine - ( C-tyrosine enrichment/ 
13 C-phenylalanine enrichment) X 100. Flux of 3-methylhistidine was 
extimated by the equation: 3-methylhistidine flux - infusion rate of 
2 2 3-methyl- H^ -histidine / 3-methyl- H^ -histidine enrichment. 
Plasma Hormone Analysis 
Plasma was analyzed for Cortisol concentration by radioimmunoassay 
(Amerlex Cortisol Kit, Amersham Corporation, Arlington Heights, IL). 
Plasma insulin concentrations were determined by radioimmunoassay by 
using bovine insulin antibody (Trenkle, 1972). Plasma glucagon was also 
determined by radioimmunoassay by using rabbit anti-porcine glucagon 
antibody (BioTek Research, Inc., Lenexa, KS). The concentration of 
insulin-like growth factor (IGF-I) in plasma was measured by Dr. Ted 
Elasasser (USDA-ARS, Beltsville, MD) by radioimmunoassay using human 
IGF-I antibody (Underwood et al., 1982). 
Statisical Analysis 
Data were statistically analyzed by analysis of variance. An F-
test with 3 and 22 degrees of freedom was used to test for diet effects 
and t-test was used to ascertain the probability of differences between 
treatments. Pearson correlation coefficients were calculated between 
the variables by SAS procedures (1985). 
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RESULTS 
Growth and feed conversion of the lambs fed leucine and its 
metabolites are presented in Table 5. Daily gain was not significantly 
different between control, KIC or IVA treatments. Leucine, however, 
tended to decrease gain (11%, p<.13) when compared to that of controls. 
Leucine-treated animals had 14% lower gain than did KIC-treated animals 
(p<.05). Feed conversion was not altered by leucine and IVA when 
compared to that of controls, whereas KIC improved feed conversion 6% 
over the controls (p<.19) and 10% over leucine (p<.03). 
The effects of feeding leucine and its metabolites on carcass 
composition are reported in Table 6. Subcutaneous backfat thickness was 
decreased 24% (p<.08) and 23% (p<.09) by KIC and IVA, respectively. 
Perirenal fat depots were decreased 44% (p<.005) and 27% (p<.07) by KIC 
and leucine, respectively. KIC increased psoas, longissimus and 
gastrocnemius muscle weight by 13% (p<.06), 8% (p<.15) and 9% (p<.13), 
respectively. IVA and leucine did not significantly alter muscle 
weight. 
Plasma metabolites of the lambs fed leucine, KIC or IVA are 
reported in Table 7. Concentrations of leucine, phenylalanine and 
tyrosine were not altered as a result of treatments imposed. Plasma KIC 
concentration was not altered by leucine and IVA but was reduced 28% by 
KIC treatment (p<.06). 
The effect of feeding leucine, KIC and IVA to lambs on plasma 
hormone concentrations are reported in Table 8. Plasma Cortisol, IGF-I, 
insulin and glucagon concentrations were not different between controls 
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Table 5. The effect of rumen-protected leucine (Leu), o^ ketoisocaproate 
(KIC) or isovalerate (IVA) fed for approximately 100 days on 
lamb growth and feed conversion 
--Probability for > F^ -
, Overall --Control vs— 
Control Leu KIC IVA S EM Model Leu KIC IVA 
n 6 6 8 6 
Daily gain, 
g 323 288 334 315 16 .22^  .13 .63 .74 
Feed/gain 4.47 4.66 4,19 4.42 .14 .19^  .61 .19 .81 
P^robability of > F for the overall ANOVA model, the contrast 
between the control vs Leu means, the contrast between the control vs 
KIC means, and the contrast between the control vs IVA means. 
S^EM is pooled standard error of the mean. 
P^robability of > F for the contrast between the KIC and Leu 
treatment means - .05. 
P^robability of > F for the contrast between the KIC and Leu 
treatment means - .03. 
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Table 6. The effect of feeding rumen-protected leucine (Leu), 
O^ ketoisocaproate (KIC) or isovalerate (IVA) for 
approximately 100 days on lamb carcass composition 
--Probability for > F^ -
, Overall --Control vs— 
Control Leu KIC IVA S EM Model Leu KIC IVA 
Final weight, 
kg 50.7 49.9 50.2 50.3 .7 .98 .54 .66 .54 
Backfat, 
mm 9.5 8.6 7.2 7.3 .9 .23 .53 .08 .09 
Renal fat, 
%° 1.56 1.14 0.87 1.33 .16 .04 .07 .005 .31 
Psoas major, 
.385 .400 .434 .412 .018 .29 .56 .06 .29 
Longissimus, , 
.885 .865 .959 .913 .035 .29° .70 .15 .58 
Gastrocnemius, 
.159 .164 .174 .152 .007 .17 .60 .13 .50 
P^robability of > F for the overall ANOVA model, the contrast 
between the control vs Leu means, the contrast between the control vs 
KIC means, and the contrast between the control vs IVA means. 
S^EM is pooled standard error of the mean. 
P^ercentage of final body weight. 
P^robability of > F for the contrast between the Leu and KIC 
treatment means - .07. 
P^robability of > F for the contrast between the KIC and IVA 
treatment means - .03. 
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Table 7. The effect of feeding rumen-protected leucine (Leu), 
0^ ,-ketoisocaproate (KIC) or Isovalerate (IVA) for 
approximately 100 days on lamb plasma metabolites 
--Probability for > F^ -
, Overall --Control vs— 
Control Leu KIC IVA S EM Model Leu KIC IVA 
__ 
uM 15.2 13.2 11.0 14.0 1.5 .27 .64 .06 .58 
Leucine, 
uM 242 254 215 247 31 .60 .80 .55 .92 
Phenylalanine, 
uM 19.7 16.6 21.0 22.2 2.1 .31 .58 .68 .32 
Tyrosine, 
uM 46,5 39.0 43.9 43.3 6.8 .97 .55 .78 .75 
3-Methylhistidine^  
uM 96.3 98.0 112.0 86.0 9.6 .39 ,90 .30 .51 
P^robability of > F for the overall ANOVA model, the contrast 
between the control vs Leu means, the contrast between the control vs 
KIC means, and the contrast between the control vs IVA means, 
S^EM is pooled standard error of the mean. 
°Only 10 lambs (control-2, Leu-3, KIC-3 and IVA-2). 
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Table 8. The effect of feeding rumen-protected leucine (Leu), 
dfketolsocaproate (KIC) or isovalerate (IVA) fed for 
approximately 100 days on lamb plasma hormones 
--Probability for > F -
, Overall --Control vs— 
Control Leu KIC IVA S EM Model Leu KIC IVA 
Cortisol, 
ug/dl 
IGF-I, 
ng/ml 
Insulin, 
ng/ml 
Glucagon, 
pg/ml 
Insulin 
/glucagon 
1.69 
203 
.87 
326 
2 . 6 8  
2.66 2.20 2.30 .48 .58 .17 .70 .61 
212 220 
.73 .99 
321 295 
201 15 .82 .67 .57 .93 
.98 .12 .40 .56 .51 .50 
295 16 .40 .81 .19 .18 
2.26 3.43 3.33 .42 .19" .50 .22 .30 
Probability of > F for the overall ANOVA model, the contrast 
between the control vs Leu means, the contrast between the control vs 
KIC means, and the contrast between the control vs IVA means. 
S^EM is pooled standard error of the mean. 
P^robability of > F for the contrast between the Leu and KIC 
treatment means - .14. 
P^robability of > F for the contrast between the Leu and KIC 
treatment means - .06. 
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leucine, KIC and IVA treatments, although KIC and IVA tended to lower 
glucagon (p<.19 and p<.18, respectively). In addition, KIC tended to 
Increase Insulln/glucagon 28% (p<.22) over that of the control and 51% 
over the leucine treatment (p<.06). 
Whole-body leucine, phenylalanine and 3-methylhistidine metabolism 
of lambs fed rumen-protected leucine, KIC or IVA are presented in Table 
9. Leucine used for protein synthesis (avg 4.42 umol/(kg*mln)) tended 
to be decreased in the animals that were fed leucine (p<.18). Leucine 
from proteolysis and absorption (avg 4.66 umol/(kg*mln)) was not altered 
due to dietary treatment. Leucine transamination to KIC (avg .83 
umol/(kg*min)) was increased for the leucine-treated lambs (p<.06). KIC 
transamination to leucine (avg .62 umol/(kg*mln)) and KIC oxidation (.22 
umol/(kg*mln)) were not affected by treatment. Phenylalanine flux (avg 
1.29 uM/(kg*min)), tyrosine derived from phenylalanine (avg 51.8%) and 
3-methylhlstidine flux (avg 12.0 nmol/(kg*rain)) were not altered due to 
treatment. 
Correlations between protein metabolism measurements and growth, 
feed conversion and carcass parameters are included in Table 10. No 
significant relationships were noted between protein metabolism 
measurements and dally gain, muscle weight and fat depots. As 
phenylalanine conversion to tyrosine increased, feed to gain was 
worsened (p<.05). 
Correlations between protein metabolism measurements and plasma 
metabolites are included in Table 11. No significant relationships were 
found between protein metabolism measurements and plasma leucine, KIC, 
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Table 9. The effect of feeding rumen-protected leucine (Leu), 
dsketoisocaproate (KIC), or isovalerate (IVA) for 
approximately 100 days on lamb whole-body leucine, 
phenylalanine, and 3-methylhistidine metabolism. 
--Probability for > F^ -
, Overall --Control vs— 
Control Leu KIC IVA S EM Model Leu KIC IVA 
Leu to protein synthesis, 
umol/(min*kg) 5.19 4.03 4.30 4.23 .58 .54 .18 .31 .27 
Leu from proteolysis and absorption, 
umol/(min*kg) 5.34 4.35 4.57 4.39 .56 .58 .23 .65 .25 
Leu to KIC 
umol/(mln*kg) .72 .97 .83 .82 .08 .30 .06 .62 .55 
KIC to Leu 
umol/(min*kg) .57 .66 .58 .67 .14 .99 .67 .97 .64 
KIC oxidation, 
umol/(min*kg) .15 .31 .26 .16 .09 .58 .26 .55 .99 
Phe flux, 
umol/(min*kg) 1.27 1.34 1.29 1.28 .14 .99 .75 .94 .94 
Tyr from Phe, 
% 47.9 56.7 52.4 50.0 8.2 .97 .53 .71 .85 
3MH flux, 
nmol/(mln*kg) 12.2 12.0 13.8 9.2 1.4 .21 .96 .53 .17 
P^robability of > F for the overall ANOVA model, the contrast 
between the control vs Leu means, the contrast between the control vs 
KIC means, and the contrast between the control vs IVA means. 
S^EM Is pooled standard error of the mean. 
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Table 10. Correlations between leucine (Leu), phenylalanine (Phe) and 
3-methylhlstldlne (3MH) flux measurements and growth, feed 
conversion and carcass composition measurements in growing 
lambs 
Gain 
Feed 
/gain 
Gastroc­
nemius Psoas 
Longlss 
-imus 
Back 
-fat 
Perirenal 
fat 
FOL* -.08 .07 .10 -.02 w
 00
 
.25 .34 
FLO^  -.12 .13 .15 -.02 -.35 .25 .29 
FAL° 
-.23 .31 .07 -.29 -.16 .03 .06 
FLA^  
CM O
 .01 -.13 -.18 -.32 .07 .30 
FOA® 
-.19 .28 .26 
CM O
 .30 -.07 -.38* 
Phe flux -.25 .21 .29 -.02 -.20 -.24 
00 o
 
Phe to 
tyrosine -.03 .40* .08 .03 -.19 .03 
CM O
 
3MH flux -.13 -.23 .02 to
 
00
 00 o
 .35* .24 
fpOL - Leu to synthesis. 
FLO - Leu from proteolysis and absorption. 
°FAL - Leu to KIC conversion. 
FLA, - KIC to Leu conversion. 
®FOA - KJC oxidation. 
*p<.10, p<.05. 
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Table 11. Correlations between leucine (Leu), phenylalanine (Phe) and 
3-methylhistidlne (3MH) flux measurements and plasma 
metabolite measurements In growing lambs 
f FOL 
FLO* 
FAL^  
FLA^  
FOAJ 
Phe to 
-Concentrations• 
Leu KIC Phe Tyr® 3MH Cort^  Ins° Glgn^  I/G® 
o
 
ro
 
-.13 -.48* -.04 .03 - . 08 .14 .33 .01 
.00 -.12 -.51* -.06 .05 -.06 .07 .31 -.05 
.18 -.30 -.06 -.40 -.27 .29 .14 .14 .08 
.06 -.26 ,00 -.18 -.27 .07 .41* .26 .29 
.09 .09 -.06 -.10 .17 .18 -.45* -.24 -.34 
-.20 -.13 -.47* -.20 -.09 .02 -.08 -.04 -.03 
.23 -.06 -.38* -.25 -.01 .06 .24 -.12 .29 
-.03 -.15 .02 -.01 -.51 .06 .20 .32 .09 
P^lasma tyrosine concentration. 
Plasma Cortisol concentration. 
P^lasma Insulin concentration. 
Plasma glucagon concentration. 
-Insulin to glucagon ratio. 
FOL - Leu to synthesis. 
®FLO - Leu from proteolysis and absorption. 
•FAL - Leu to KIC conversion. 
FLA - KIC to Leu conversion. 
F^OA - KJC oxidation. 
*p<.10, p<.05. 
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Table 12. Correlations between leucine (Leu), phenylalanine (Phe) and 
3-methylhistidine (3MH) flux measurements in growing lambs 
Phe 
FOL* FLO^  FAL° FLA^  FAO® 
Phe 
Flux 
to 
Tyr 
3MH 
Flux 
FOL* 1.00 ,33 .46* -.34 .13 .30 .12 
FLO^  1.00 ,33 .35 -.18 .14 .29 .12 
FAL° 1.00 .72*** -.07 .17 .30 -.05 
FLA^  1.00 -.74*** .12 .42* -,04 
FOA® 1.00 -.01 -,30 -,04 
Phe flux 1.00 .54*** -,25 
Phe to 
tyrosine 1.00 -,40* 
3MH flux 1.00 
FOL - Leu to synthesis. 
FLO » Leu from proteolysis and absorption. 
°FAL - Leu to KIC conversion. 
FLA - KIC to Leu conversion. 
®FOA - KIC oxidation. ... 
p<.10; p<.05; p<.0001; p<.0001. 
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tyrosine and 3-methylhlstidine. As phenylalanine flux and phenylalanine 
conversion to tyrosine increased, plasma phenylalanine concentration 
decreased (p<.05 and p<.10, respectively). As the concentration of 
plasma insulin increased, KIC oxidation decreased and KIC to leucine 
conversion increased (p<.05 and p<.10, respectively). 
Correlations between protein metabolism measurements are included 
in Table 12. As protein synthesis increased, leucine from proteolysis 
and absorption and KIC conversion to leucine were increased (p<.0001 and 
p<.05, respectively). A positive relationship was observed between KIC 
conversion to leucine and leucine conversion to KIC (p<.0004). 
Additionally, as KIC conversion to leucine increased, KIC oxidation 
decreased (p<.0002). As KIC conversion to leucine was increased, 
phenylalanine conversion to tyrosine was increased (p<.06). A positive 
relationship between phenylalanine flux and phenylalanine conversion to 
tyrosine was noted (p<.005), whereas a negative relationship between 
3-methylhistidine flux and phenylalanine conversion to tyrosine was 
observed (p<.06). 
Discussion 
While gain and carcass parameters were similar to those reported in 
previous trials, the major finding in this study is that KIC did not 
appear to alter protein metabolism as measured by leucine, phenylalanine 
and 3-methylhistidine flux models. KIC did not increase leucine to 
whole-body protein synthesis nor decrease leucine from whole-body 
proteolysis as might be predicted from previous reports (Kirsch et al.. 
127 
1976; Chua et al., 1979; Poso et al., 1982; Tischler et al., 1982). 
Whole-body phenylalanine flux, a measurement of protein turnover 
independent of leucine metabolism, also was not altered by KIC 
treatment. Finally, muscle protein degradation, as measured by 3-
methylhistidine flux, was not decreased by KIC. 
There may be several reasons that an effect of KIC on protein 
metabolism was not detected. Firstly, the lambs in this study were 
over-night fasted, and it is possible that KIC may exert its effects on 
protein metabolism when animals are in the fed state. Animals in the 
fed state would have more substrates with which to increase muscle mass, 
and it is during the fed state that most of protein deposition takes 
place. Additionally, any effect KIC would have on increased insulin to 
glucagon ratios would be more dramatic during the fed period, when this 
ratio determines the amount of amino acids utilized for glucose 
production versus the amount utilized for protein synthesis. 
Secondly, growth response to KIC has been greater in the early 
portion of each of the previous trials reported (Flakoll et al., 1988a, 
b). Net protein gain is greater during the early phase of lamb growth; 
therefore, the effect of KIC on protein metabolism may be greater during 
this phase. These studies measuring protein metabolism were conducted 
later on in the trials when the lambs were older and possibly less 
responsive to KIC. 
Thirdly, the methods used to estimate protein metabolism may not 
have been specific to the organs that KIC affected. The leuclne-KIC 
model estimates whole-body protein synthesis, proteolysis and 
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absorption, and oxidation; the phenylalanine model measures whole-body 
protein turnover; and the 3-methylhlstidlne model measures muscle 
(skeletal and gut) protein breakdown. If muscle protein synthesis was 
increased without significantly increasing whole-body protein synthesis, 
these methods would not detect a change. For example, KIC could be 
directing protein from gut and liver tissues to muscle tissue. This 
partitioning of nutrients needs closer examination. 
Parameters of leucine kinetics in this trial are in agreement with 
those in previously reported studies (Grisdale, 1986; Nissen and 
Ostaszewskl, 1985; Davis et al., 1981; Pell et al., 1986). In the 
present experiment, only 16% of the leucine flux was transaminated to 
KIC and only 11% of the leucine produced was the result of 
transamination from KIC. Other reports of transamination in lambs have 
shown leucine conversion to KIC to be 18% of the total leucine flux 
(Nissen and Ostaszewskl, 1985). Conversely, reports with nonruminants 
have demonstrated leucine to KIC conversion to be 59% in humans 
(Matthews et al., 1981), 62% in the pig (Helland et al., 1986) and 82% 
in the dog (Nissen and Raymond, 1981). Clearly, this is a distinct 
difference between ruminants and nonruminants. 
Because of their decreased transaminase activity, ruminants may be 
more responsive than nonruminants to dietary inputs of leucine in terms 
of plasma leucine concentration. Leucine-treatment tended to decrease 
gain in lambs, which appeared to be through decreased feed Intake. 
Plasma ratios of leucine to phenylalanine or tyrosine were 20% greater 
in the leucine-treated lambs than in the controls and 33% greater than 
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the KIC-treated lambs. This imbalance of leucine to phenyalanine and 
tyrosine may be the reason for depressed feed intake. 
Although there are no previous reports of phenylalanine metabolism 
in ruminants, Moldawer et al. (1983) reported pheylalanine flux in 
postabsorptive rats to be 6.9 umol/(kg*min), which is considerably 
greater than the results reported in the present experiment. The 
leucine flux they reported (10.9 umol/(kg*min) was also higher than the 
present reports. However, they also found significant conversion of 
phenyalanine to tyrosine. They estimated that 54% of tyrosine oxidized 
was derived from phenylalanine, which would be in close agreement with 
the present data in lambs. These data present evidence confirming that 
estimates of protein turnover by tyrosine needs to include contributions 
from phenylalanine flux. 
There are no known previous reports of plasma 3-methylhistidine 
flux in lambs. In previous work where 3-methylhistidine metabolism was 
examined in lambs (Harris and Milne, 1980), it was found that 
3-methylhistidine transfer from blood to urine was slow compared with 
that in humans (Long et al., 1975), rats (Young et al., 1972), rabbits 
(Harris et al., 1977) or cattle (Harris and Milne, 1981). Less than 50% 
of a labelled 3-methylhistidine was recovered from lamb urine after 
7 days. In contrast, ^ C^-labelled 3-methylhistidine was almost 
quantitatively collected in the urine of humans, rats, rabbits and 
cattle within 2 to 7 days. This difference is thought to be due to the 
large 3-methylhistidine pools within the lamb body in comparison to 
urinary output and makes analysis of urinary 3-methylhistidine in lambs 
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an unacceptable method for estimation of muscle protein breakdown. 
Turnover of the plasma pool of 3-methylhlstidlne may, however, provide 
as alternative method of measuring muscle protein breakdown. Further 
studies are necessary to validate this methodology in lambs. 
Although correlation coefficients calculated in this experiment 
indicate only relationships and not causes and effects, several 
conclusions can be drawn. Wlien comparing the measurements of protein 
metabolism with measurements of growth, feed conversion and carcass 
composition, it is of note that very few significant correlations were 
found. This suggests that the prediction of long-term parameters is 
difficult with protein metabolism measurements made during short-term 
Infusion studies. It also stresses the Importance of when these 
measurements are taken. 
The only significant relationship found between performance 
measurements and protein metabolism measurements was that phenylalanine 
to tyrosine conversion was positively correlated with feed conversion, 
meaning as more phenylalanine was converted to tyrosine and feed 
conversion tended to be worsened. An additional observation was that, 
as the conversion of phenylalanine to tyrosine Increased, phenylalanine 
flux was Increased and plasma phenylalanine concentration was decreased. 
The reasons for this are unclear. 
When comparing the various parameters of the leucine model, 
increasing the interconversion of leucine to KIC and KIC to leucine is 
positively correlated with KIC oxidation. This would stand to reason as 
it has been demonstrated that feeding high protein diets (Wohlhueter and 
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Harper, 1970), leucine (Wohlhueter and Harper, 1970) or KIC (Khatra et 
al., 1977) to rats Increases branched-chain amino acid dehydrogenase 
activity. Additionally, in the present study protein synthesis was 
positively correlated with both proteolysis/absorption and the amount of 
KIC converted to leucine, suggesting that increased leucine entry may 
increase protein synthetic rate. 
Few of the measurements between leucine, phenylalanine and 
3-methylhistidine models were significantly correlated. The only trends 
were that KIC conversion to leucine tended to be positively correlated 
with phenylalanine to tyrosine conversion, whereas 3-methylhistidine 
flux tended to be negatively correlated with phenylalanine to tyrosine 
conversion. The significance of these relationships is unclear, but the 
apparent lack of significant relationships between the three models 
raise questions regarding the sensitivity of such models and emphasizes 
the caution which must be taken when interpreting data from a single 
amino acid flux model. 
In conclusion, KIC and its metabolites, leucine and IVA, did not 
alter protein metabolism in overnight-fasted lambs as measured by 
leucine, phenylalanine or 3-methylhistidine flux models suggesting that 
KIC does not increase growth and carcass composition by sparing protein 
of lambs in the nonfed state. 
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GENERAL DISCUSSION 
The major finding from these experiments is that ^ ketoisocaproate 
(KIC) improves gain and feed conversion in cattle and lambs. 
Additionally, external and internal fat depots were decreased, psoas, 
gastrocnemius and longissimus muscle weights were increased, and humerus 
and tibia bone weights were increased. 
When considering the possible mechanisms for KICs action, foremost 
consideration must be given to KICs proposed effects of increasing 
protein synthesis and decreasing proteolysis. These effects would 
explain improved gain and feed conversion, increased muscle mass and 
decreased fat deposition. However, when three independent models 
measuring protein metabolism were used on KIC-treated lambs, no 
improvement in whole-body protein synthesis, whole-body proteolysis and 
muscle proteolysis were detected. 
It is not possible for muscle mass to be increased without in some 
way altering protein metabolism. It needs to be kept in mind, however, 
that the protein turnover measurements were made during two hours of one 
day out of the approximately 100 days of treatment. This fact allows 
for several possible explanations as to how muscle mass could be 
increased, although protein metabolism measurements were not altered. 
Firstly, most protein deposition in an animal occurs during and 
shortly after a meal. Additionally, much of the energy required for 
protein turnover is spent during this same period. The reported protein 
metabolism studies were conducted on lambs after an over-night fast. If 
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protein deposition is increased by KIC during or shortly after a meal, 
it would not be detected by these experiments. 
Additionally, it was demonstrated, in the experiments in which it 
was measured, that KIC increased the ratio of insulin to glucagon. Any 
effect KIC would have on increased insulin to glucagon ratios would 
be most dramatic during the fed period when this ratio determines the 
amount of amino acids utilized for glucose production versus the amount 
utilized for protein synthesis. Increased insulin to glucagon would 
direct more amino acids to protein synthesis and result in fewer being 
catabolized. Therefore, further research examining the effects of KIC 
on ruminant protein metabolism during a fed state would certainly be 
warranted. 
Secondly, during the earlier growth phase of a ruminant, a greater 
portion of body weight gain is the result of muscle gain, as opposed to fat 
or bone gain, than in the later growth phase. Therefore, net protein 
deposition is greater during this early phase of growth. If net protein 
deposition is increased more dramatically in the early portion of the 
lamb growth phase, the effect of KIC on protein metabolism and 
deposition would be expected to be greater during this period. Protein 
metabolism studies reported here were executed in the later portion of 
the growth phase and would not detect any such alterations. Growth, 
however, was measured at weekly or bi-weekly intervals during the 
reported experiments and was found to be increased more dramatically 
during the early portion of each experiment reported. 
Thirdly, it could be postulated that KIC increased net protein 
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deposition by suppressing stress related catabolism. Again, most of the 
chronic stress in these trials occurred early in each experiment when 
animals were adjusting to new environments, pathogens, different feed 
sources and human contact through feeding and handling. Protein 
metabolism was not measured during this period. The demonstrated 
growth-response to KIC early in each trial would also support this 
theory. Additionally, concurrent studies indicated that lymphocyte 
blastogenesis and antibody production, which are normally depressed 
during stress, were increased by KIC treatment. It is possible that the 
possibility of KIC moderating the physiological results of stress has 
been overlooked in the clinical trials in which KIC was used under 
stressful conditions such as septis, renal or hepatic failure and 
starvation. Further work examining the effect of KIC on protein 
turnover during stress is necessary. 
Finally, the methods used to estimate protein metabolism may not 
have been specific to the area that KIC affected. The leucine-KIC model 
estimates whole-body protein synthesis, proteolysis and absorption, and 
oxidation; the phenylalanine model measures whole-body protein turnover; 
and the 3-methylhistidine model measures muscle (skeletal and gut) 
protein breakdown. If muscle protein synthesis was increased without 
significantly increasing whole-body protein synthesis, these methods 
would not detect a change. For example, KIC could be directing protein 
from gut and liver tissues to muscle tissue. Studies examining the 
effects of KIC on protein metabolism of various ruminant tissues in 
vivo, tracing the flow of nutrients to the various organs during KIC 
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treatment, Is necessary to fully understand the mechanism of KIC action. 
It has been argued that selected amino acid tracer studies to 
estimate protein metabolism may not correlate well with actual nitrogen 
balance due to methodological problems. Although whole-body nitrogen 
balance was not measured, this was also suggested in the present 
studies. If this is the case then the disparity between growth and 
muscle weights, and protein metabolsim studies are easily explained. 
Clearly, nitrogen balance studies with growing ruminants would 
help explain the effects of KIC on protein metabf^ lism. 
Another possible mechanism that KIC may improve growth could be 
through an improvement of immune function. Improved immune function 
could translate into fewer sub-par performing animals and an overall 
increase in average performance. 
It was also apparent from the reported experiments that other 
metabolites of KIC, leucine and isovalerate did not produce similar 
responses as did KIC. Therefore, either the physiology of leucine and 
IVA metabolism do not allow them to produce effects similar to KIC, or 
it does not appear that KIC exerts its effects through these 
metabolites. 
Because KIC is metabolized mainly by gut and liver tissues, it 
would follow that gut and liver tissues would be the main location of 
KIC action. Several speculations about the mechanism of KIC in the gut 
and liver can be made. First, the splachnic area has the greatest rate 
of protein turnover in the body; therefore, KIC could affect growth and 
muscle deposition by lowering gut and liver protein turnover. Second, 
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KIC could affect cholesterol and ultimately steroid hormone metabolism 
through Its catabollsm to f-hydroxy-p-methylglutaryl CoA or Its 
oxidation to (Jj)-hydroxy-^ -methyIbutyrate; the liver Is the major tissue 
that produces cholesterol. KIC could also affect liver cholesterol 
metabolism by altering cholesterol transport protein production, because 
It has been demonstrated that KIC Increased another liver transport 
protein, albumin. KIC could alter gut and liver cell metabolism 
directly, possibly resulting in a sparing of nutrients crossing the 
splanchnic bed. Additionally, the gut produces several hormones, and 
KIC could alter any of these. The possible interactions of KIC with gut 
and liver tissues are immense and definitely require further 
examination. 
It could be argued that the growth response to KIC may be through a 
ruminai effect on microorganisms as has been demonstrated with branched-
chain fatty acids. However, data from the reported experiments would 
indicate that the effect of KIC Is postruminal. First of all, KIC was 
effective when delivered intraperltoneally. In addition, oral delivery 
was more effective when it was protected from ruminai degradtlon. 
KIC produced similar resposes to gain in lambs when delivered 
orally at 15 g/d (1% of intake) unprotected from ruminai degradation, 
Intraperltoneally at 3 g/d (~,2% of Intake), and orally protected from 
ruminai degradation at .75 g/d (.05% of Intake). Other dosage levels in 
lambs were not tested. In the only dose-response study conducted, KIC 
produced a better gain response in cattle when fed at 1.8 g/d (.02% of 
intake) than at 6.4 (.07% of Intake) or 18.0 g/d (.20% of intake). 
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This optimal response was greater than for the lambs fed ruminally-
protected KIC. On a body-weight basis, the optimal dose for the cattle 
fed KIC was almost four-fold greater than the dose for the lambs fed 
ruminally-protected KIC (4 versus 15 mg KlC/kg body weight). The dosage 
delivered to the lambs, therefore, may have been higher than optimum. 
The optimal amount of KIC under various conditions is an area that will 
require considerable research. 
In each experiment conducted, KIC was administered with a basal 
diet relatively high in protein and energy. The response KIC would 
evoke if administered to animals on a lower plane of nutrition will need 
to be addressed in further research. If KIC spares protein and (or) 
energy, it may require less nutrient input to obtain equivalent gains. 
Internal and external fat depots consistently were decreased in the 
animals administered KIC. Additionally, milk fat production in 
lactating ruminants has been demonstrated to be increased. There are 
several reasons that could be postulated for these observations. The 
first involves KICs proposed decrease of protein turnover. In the 
growing ruminant, the energy that would be saved by a decrease in 
protein turnover would be directed to Increased protein muscle 
synthesis. However, in the lactating ruminant, it appears that these 
energy savings would be directed to the mammary gland. A second 
possibility is if KIC treatment would increase lipolysis or suppress 
lipogenesis in adipose tissue increased muscle growth and decreased fat 
depots would be predicted. Finally, KIC is directly linked to fat 
metabolism through its conversion to ketone bodies and 
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l^ hydroxy-^ -methylglutaryl Co A, a precursor for cholesterol and 
steroid hormones. Ketone bodies, however, have been shown to suppress 
lipogenesis. Therefore, no clear mechanism for KIC to act on fat 
metabolism can be drawn from the present studies. 
In conclusion, while the mechanism(s) is not entirely clear, KIC 
improves cattle and sheep growth and efficiency, decreases fat and 
increases muscle weight. These improvements certainly have the 
potential for economic improvement by the ruminant producer. However, 
there is much yet to be learned about the physiological metabolism of 
KIC, which may allow researchers to further improve the efficiency of 
ruminant production. 
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APPENDIX A 
Short-term Intravenous Administration 
of qpketoisocaproate (KIC) to Lambs 
In a preliminary experiment, ewes weighing 29 kg were injected 
intravenously via indwelling jugular catheters for 21 days with saline 
or sodium-KIC. Six lambs were injected daily with 25 ml saline, 4 lambs 
with 1 g of Na-KIC in 25 ml saline and 4 lambs with 2 g of Na-KIC in 25 
ml saline. After injection, 5 ml of heparenized saline was injected to 
flush the cathetors. The lambs were housed together in one group, but 
were fed individually a corn-soybean meal based diet (Table 1). Feed 
was given twice daily with continual access to water. Body weight gain 
and feed intake measurements were made weekly. Wool growth was measured 
by clipping a known marked area on each side of each lamb at both the 
start and at the end of the experiment. Statistical analysis was made 
by analysis of variance and comparing the KIC treatment means with the 
control mean via t-test. 
Lamb growth and feed conversion are presented in Table 2. Daily 
intravenous injections of 1 or 2 g of KIC increased gain 14% (p<.09) and 
29% (p<.01), respectively, above the saline treated animals. Neither 
daily feed intake nor feed conversion were altered by intravenous KIC 
treatment (p<.12 and p<.15, respectively). Wool gain was not 
significantly altered by KIC. 
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Table 1. Composition of basal diet fed lambs infused with daily 
intravenous doses of 0^ -ketoisocaproate (KIC) 
Ingredient % of total mix 
Corn grain 48.70 
Dehydrated alfalfa* 25.00 
Expeller soybean meal^  19.00 
Molasses, sugarcane 5.00 
Corn oil° 1.00 
Limestone .74 
Salt .50 
Vitamin A premix^  .05 
Trrfce mineral premix® .01 
Calculated: 
Net energy-maintenance, Mcal^  1.82 
f Net energy-gain. Meal 1.18 
Metabolizable protein, %® 9.7 
Leucine, 1.85 
f20% crude protein. 
Soy-Plus, West Central Cooperative, Ralston, lA. 
M^azola, CPG International Inc., Cedar Rapids, lA. 
5,200,000 lU vitamin A/kg, Hoffmann-LaRoche, Inc., Nutley, NJ. 
®Ca, 13-15%; Zn 12%; Mn 8.0%; Fe 10%; Cu 1.5%, I .2%; Co .1%, 
Calcium Carbonate division of J. M. Huber Corporation, Quincy, IL. 
Calculated from National Research Council values (National 
Research Council, 1982). 
C^alculated from Burroughs et al. (1974). 
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Table 2. The effect of daily intravenous infusion of d^ ketoisocaproate 
(KIC) for 21 days on lamb growth, feed conversion, and wool 
growth 
NaKIC Infused Daily, g 
Parameter 0 1 2 SEM^  
n 4 4 5 
Daily gain, g 209 244+ 265** 13 
Daily intake, g 1034 1161* 1143 52 
Feed/gain 5.0 4.8 4.3* .3 
Fat-free wool gain, 
mg/(cm2'd) 5.4 4.5 4.5 .5 
S^EM is pooled standard error of the mean. 
*P<.15, ^ P<.10 and **P<.01 that treatment mean are not 
different from the control. 
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APPENDIX B 
Liver Lipid Concentration and Composition of Lambs Receiving Daily 
Intraperitoneal Injections of a(-ketolsocaproate (KIC) 
Liver samples were removed from lambs receiving daily 
intraperitoneal injections of KIC (Exp. 1, Section I). Liver lipids 
were extracted by chloroform-methanol extraction (2:1, v:v; Rotenberg 
and Christensen, 1976). Extracts were dried and total lipid weight 
recorded. The lipid extracts were resuspended in isopropanol for 
enzymatic analysis of total cholesterol (Centrifichem, Baker Instruments 
Corporation, Allentown, PA). Fatty acid composition of the liver lipid 
extract was determined by gas chromatography (Varian 3700G) of the fatty 
acid methyl esters (Arrendale et al., 1983). 
The effects of intraperitoneal administration of KIC on lamb liver 
composition is reported in Table 1. Liver fat and cholesterol were 
reduced by 21% (p<.ll) and by 25% (p<.05) due to KIC treatment. Liver 
C16, C17, and C18 fatty acids were lowered with KIC treatment by 27% 
(p<.06), 41% (p<.01) and 24% (p<.08), respectively. Total unsaturated 
fatty acids (C16:l, C18:1, C18;2, and C18:3) were not significantly 
decreased by KIC treatment, whereas total saturated fatty acids were 
decreased 26% (p<.05). 
The ruminant obtains fatty.gcids from two sources: dietary 
absorbtion or de novo synthesis. Due to hydrogénation by microorganisms 
in the rumen, fatty acids absorbed from the gut and presented to the 
liver via the portal system are mainly saturated. Therefore, steric 
acid (16:0) is the major fatty acid supplied by the diet. The primary 
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precursor for fatty acids synthesis by the ruminant is 
extramitochondrial acetyl CoA and not glucose. Minimal fatty acid 
synthesis occurs in the ruminant liver due to the low activity of 
hepatic citrate lyase, whereas adipose tissue is responsible for 
approximately 90% of fatty acid synthesis in ruminants. De novo 
synthesized fatty acids are readily desaturated (25 to 75% of total 
18:0 synthesized is desaturated) in preference to those of exogenous 
origin. Therefore, as fatty acid synthesis is increased, desaturase 
activity is Increased. 
Liver has minimal fatty acid synthetase and desaturase activities. 
However, the liver is the major site of fatty acid removal (25% of total 
fatty acids). Liver uptake of fatty acids is a function of total plasma 
fatty acid concentration. Shorter chain and desaturated fatty acids are 
taken up by the liver faster than longer chain and saturated fatty 
acids. 
In the present experiment, liver saturated fatty acids were reduced 
while unsaturated fatty acids were not altered by KIC treatment. The 
ratio of saturated to unsaturated fatty acids could be lowered by 1) 
Increasing the adipose desaturase activity, which usually means an 
increase in de novo synthesis, 2) Increasing the preference of the liver 
for unsaturated fatty acid uptake, and 3) increasing lipolysls. Plasma 
fatty acid content Increased in Exp. 2 and liver lipid and cholesterol 
content were decreased in the Exp. 1, suggesting that an increase in 
lypolysls may be likely. Further research is required to specifically 
define the effect of KIC on lipolysls and llpogenesls. 
150 
Table 1. Effects of daily intraperitoneal injections of 
Wfketoisocaproate (KIC) for approximately 120 days on lamb 
liver lipid composition 
Parameter Saline KIC SEM* P<^  
Liver lipid, % 4.09 3.18 .38 .11 
Liver cholesterol, % .264 .197 .023 .05 
Liver fatty acids, % 
C16 .7127 .5180 .0690 .07 
C16:l .1167 .1010 .0156 .50 
C17 .1077 .0639 .0111 .01 
C18 .9726 .7369 .0893 .08 
018:1 1.2213 .9567 .1263 .15 
CIS: 2 .9042 .7578 .0936 .28 
C18:3 .0501 .0462 .0058 .64 
Total saturated 1.7931 1.3188 .1585 .05 
Total unsaturated 2.2923 1.8617 .2324 .21 
Saturated/unsaturated .788 .719 .034 .16 
P^ooled standard error of the mean. 
P^robability that treatment means are not different. 
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APPENDIX C 
Small Intestines, Mesenteric Fat, Lymph Nodes, and Separable Carcass 
Fat, Lean and Bone from Lambs Fed e(.-ketolsocaproate (KIC), Leucine 
(Leu) and Isovalerate (IVA; Exp. 2, Trial 2, Section 2) 
Small intestine, mesenteric fat, lymph nodes, and separable 
carcass fat, lean, and bone were sampled in Trial 2 of Exp. 2 in Section 
2. Small intestines was removed from the lambs at termination, stripped 
of dlgesta, and weighed. Mesenteric fat was dissected from intestinal 
and stomach tissue and weighed. Right and left cervical and illiac 
lymph nodes were dissected from frozen carcasses and weighed. Carcasses 
were physically separated into fat, lean, and bone tissue and weighed. 
Results are included in Table 1. 
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Table 1. The effect of feeding rumen-protected leucine (Leu), 
Afketoisocaproate (KIC), or isovalerate (IVA) for 
approximately 100 days on weight of lamb small intestines, 
mesenteric fat, lymph nodes and carcass fat, lean and bone 
Control Leu KIC IVA SEM^  P>F^  P>F° 
Small intestine, % 0.78 0.85 0.78 0.81 .11 .25 .98 
Mesenteric fat, % 3.48 3.92 3.71 3.93 .49 .99 .53 
Lymph nodes, % x 1000 : 
Right cervical 10.8 14.8 11.7 11.1 1.7 .34^  .71 
Left cervical 9.9 14.9 13.1 11.1 1.5 .14® .17 
Right ileac 3.1 3.2 3.2 2.7 .4 .71 .84 
Left ileac 2.8 3.8 2.6 2.5 .4 .09^  .67 
Carcass, % 
Fat 27.1 26.8 28.6 29.6 1.3 .56 .55 
Lean 53.1 54.5 52.6 54.5 1.0 .51 .76 
Bone 19.8 18.7 18.8 18.1 .7 .31 .32 
S^EM is pooled standard error of the mean. 
P^robability of > F for overall model. 
P^robability of > F for contrast between control and KIC means. 
P^robability of > F for contrast between control and leucine means 
— .11. 
P^robability of > F for contrast between control and leucine means 
- .03. 
P^robability of > F for contrast between control and leucine means 
-  . 0 8 .  
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APPENDIX D 
Summary of Observations Concerning Gas Chromatography/Mass Spectroscopy 
(GC/MS) Method for 3-Methylhlstldlne (3MH) 
1. Acetonitrile is a better solvent than pyridine. 
2. Moderate heat (-70 C. for 1 hr) after derivatization increases 
abundance. 
3. Butylsilyltrifluroacetamide (BSTFA) results in greater 
abundance than tributyldimethylsilane (TBDMS) monitoring BSTFA Q 196 AMU 
and TBDMS @ 340 AMU. 
4. There were no changes in abundance after lengthening or 
shortening purge time. 
5. There were no changes in abundance when injector temperature 
was lowered from 250 to 150° C. 
6. No 3MH was detected in keto rinse from the cation column. 
7. With 2 ml of cation resin (50%), 25% NH^ OH is strong enough to 
elute 3MH (25 to 100 % was tested). 
8. Decreasing the oven temperature to 50° C initially, while 
maintaining the injector temperature at 250° C dramatically increased 
abundance. 
9. Siliconizing glass dram vials appeared to improve abundance 
very little (however, it may help older vials). 
10. Increasing the amount of 3MH standard resulted in a linear 
(corr -.98) increase in abundance. 
11. Increasing the amount of plasma resulted in a linear (corr 
-.97) increase in abundance. 
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12. Differing ratios of d-3 3MH and 3MH stds with or without 1 ml 
of sheep plasma (2,0;1.5,.5;1,1;.5,1.5;0,2 or 
1,0;.75,.25;.5,.5;.25,.75;0,1) resulted in linear curves. 
13. TBDMS without 1% TBDMClS catalyst Is a better dervatlve than 
BSTFA, as it consistently produces abundances greater than or equal to 
BSTFA, and it is far more stable. 
14. HCl gassing of dried sample before derivatization resulted it 
slightly greater abundances, especially with BSTFA. 
15. Heating samples to 105° C for 15 to 20 min. after drying 
greatly improves the abundance yields. 
16. Acetone and 1.5 N perchlorate protein precipitation appear to 
be equivalent. 
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APPENDIX E 
Outline of 3-Methylhlstldlne Analysis 
1. Add sample (2 ml if plasma) + 177 nmol 1-methylhistidine to 10 
ml plastic tube. 
2. Deprotelnize with 3.0 ml 1.5 N HClO^  per ml sample. 
3. Vortex and centrifuge (§ 3000 for 15 min. 
4. Prepare cation columns with 2 ml Dowex resin (50%). Wash with 
4 ml .01 N HCl. 
5. Pour sample over column. Rinse with 3 ml of 0.01 N HCl. 
Discard rinse. 
6. Elute aminos with 4 ml 25% NH^ OH. Collect in very clean dram 
vials. 
7. Dry at 55° C. under nitrogen. When dry increase temperature to 
105° C for 15 to 20 min. 
8. Cool. Add 100 ul acetonitrile (Regis Chemical Co., Morton, IL) 
and 100 ul TBDMS without TBDMCIS (Regis Chemical Co., Morton, IL). Cap 
tighlty with TEFLON-lined caps. 
9. Vortex thoroughly and place in 80 C. oven for 1 hour. 
10. Label plastic conical autosampler vials and place in same oven 
for 1 hr to dry. 
11. Remove samples and vials from oven, cool, and transfer samples 
from dram vials to autosampler vials, cap, and place in autosampler 
rack. 
12. Inject into GC/MS (Hewlett-Packard 5890/5790a) using 
DATA:MHSIMB.M, which monitors 238.1, 239.1, 240.1, and 241.1 AMU with 
157 
Injector and detector @ 285 C., and oven initially at 50 C. Oven 
temperature Initial temperature at 50° C, ramp 1 at 40° C/mln to 220°, 
hold for 5 min., and ramp 2 at 40°/min to 300° C, hold for 1.3 min. 
Retention time is roughly 7.8 min. Column is 25 m x .22 mm i. d. x ,11 
um film thickness, crossllnked silicone gum phase capillary column (HP-
1, Hewlett-Packard, Avondale, PN). 
158 
2 . 5 E G  
2.0E6 
l.SEB 
lU 
o 
c 
n) 
T3 
C 
3 
^  I . B E G  
5 . 0 E 5 '  
T I C  o f  D f l T R : 3 M H S C R N . D  
0-^—1—I—I—I—I—I—I—I I I I I I I I I 
G . 5  7 . 0  7 . 5  0 . 0  .  8 . 5  
T i m e  ( m l n . )  
9 . 0  
Figure 1. Total ion chromatograph (TIC) of 3-methylhistidine (retention 
time - 7.8 rain) on a Hewlett-Packard 5790a mass selective 
detector under the conditions described in the outline above 
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Figure 2. Spectral scan of 3-methylhistidine (retention time - 7.8 
min) on a Hewlett-Packard 5790a mass selective detector under 
the conditions described in the outline above 
160 
I o n  2 3 8 . 1 0  a m u .  f r o m  D A T A : 2 3 8 . D  
9 . 7 E 5 1  
<u 
u 
c 
«j 
13 
c 
3 
Œ 
0 ' I I I I I I I I r k II I I 
6 . 5  7 . 0  7 . 5  
T i m e  ( m l n . )  
I—r 
8 . 5  
1—I—I 
9 . 0  
%  1 . 5 E 5 -
c  1 . 0 E 5 -
- g  5 . 0 E 4 -
3 0  
Œ 
I o n  2 3 9 . 1 0  a m u .  f r o m  D A T A : 2 3 8 . D  
6 . 5  7 . 0  7 . 5  8 . 0  8 . 5  
T i m e  ( m i n . )  
9 . 0  
% 4 . 0 E 4  
I o n  2 4 0 . 1 0  a m u .  f r o m  D A T A ; 2 3 8 . D  
• ^ 2 .  0 E 4  •  
7 . 0  7 . 5  8 . 0  
T i m e  ( m i n . )  
8 . 5  9 . 0  
2 . 2 E 4 1  
u 
u 
c 
(*) 
T3 
c 
3 
S3 
Œ 
0-^  
I o n  2 4 1 . 1 0  a m u .  f r o m  D A T A : 2 3 8 . D  
I I i" I I I I I I I I I I I I I 
6 . 5  7 . 0  7 . 5  8 . 0  
T i m e  ( m i n . )  
r=Z>T ( 1,'i / 
8 . 5  
-1—I—I 
9 . 0  
Figure 3. Selected ion monitoring (SIM) chromatogiaphs.of 
3-methylhistidine with a Hewlett-Packard 5790a mass selective 
detector monitoring for masses 238.1, 239.1, 240.1 and 241.1 
AMU as described in the outline above 
*** Height Percent *»• 
Report by Retention Time 
Operator: 
Sample Info : 
Miac Info: 
Integration File Name : DATA:238.I 
Method index : 3 
27 Nov 87 10:01 pn 
Bottle Number : 1 
Ret Time Signal Oescr Type Area Height % Pk % Sg Z LPk % LSg 
7.803 Mass 241.10 anu BB 363385 21485 1.74 100.00 
7.802 Mass 240.10 amu BB 86GG95 50798 4.11 100.00 
7.803 Mass ' 239.10 amu BB 32E42E9 182921 14.80 100.00 
2.13 100.00 
5.18 100.00 
18.G5 100.00 
7.802 Mass 238.10 amu BV 17825410 980912 79.35 100.00 100.00 100.00 
Figure 4. Report from chromatograph in Figure 3 
